50_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS 1_CD ._.
Corporate_JJ restructuring_NN During_IN the_DT period_NN the_DT Group_NNP carried_VBD out_RP a_DT corporate_JJ restructuring_NN including_VBG the_DT introduction_NN of_IN a_DT new_JJ holding_VBG company_NN ,_, Hikma_NNP Pharma_NNP PLC_NNP ,_, incorporated_VBN in_IN Great_NNP Britain_NNP as_IN a_DT public_JJ limited_JJ company_NN on_IN 8_CD September_NNP 2005_CD ._.
Hikma_NNP Pharma_NNP PLC_NNP changed_VBD its_PRP$ name_NN to_TO Hikma_NNP Pharmaceuticals_NNP PLC_NNP on_IN 19_CD September_NNP 2005_CD and_CC on_IN 31_CD October_NNP 2005_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP acquired_VBD the_DT issued_VBN share_NN capital_NN of_IN Hikma_NNP Pharma_NNP Limited_NNP ,_, the_DT former_JJ holding_VBG company_NN ,_, for_IN the_DT issue_NN of_IN shares_NNS to_TO shareholders_NNS on_IN the_DT basis_NN of_IN four_CD shares_NNS for_IN every_DT one_CD share_NN held_VBN in_IN Hikma_NNP Pharma_NNP Limited_NNP ._.
Prior_RB to_TO 31_CD October_NNP 2005_CD ,_, Hikma_NNP Pharmaceuticals_NNP PLC_NNP had_VBD not_RB commenced_VBN trading_NN or_CC made_VBN any_DT profits_NNS or_CC losses_NNS ._.
On_IN 1_CD November_NNP 2005_CD the_DT shares_NNS of_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP were_VBD listed_VBN on_IN the_DT London_NNP Stock_NNP Exchange_NNP ._.
The_DT corporate_JJ restructuring_NN was_VBD accounted_VBN for_IN using_VBG merger_NN accounting_NN principles_NNS ._.
The_DT results_NNS of_IN the_DT Company_NN and_CC its_PRP$ subsidiaries_NNS have_VBP been_VBN presented_VBN on_IN a_DT pro_FW forma_FW basis_NN for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2005_CD and_CC 31_CD December_NNP 2004_CD as_IN the_DT Directors_NNS believe_VBP this_DT information_NN is_VBZ more_RBR meaningful_JJ to_TO readers_NNS than_IN information_NN for_IN the_DT period_NN from_IN 8_CD September_NNP 2005_CD to_TO 31_CD December_NNP 2005_CD ._.
The_DT Directors_NNS believe_VBP that_IN this_DT presentation_NN is_VBZ necessary_JJ to_TO present_VB a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT results_NNS of_IN the_DT Company_NN and_CC its_PRP$ subsidiaries_NNS for_IN the_DT period_NN ._.
The_DT Hikma_NNP Pharmaceuticals_NNP PLC_NNP consolidated_JJ statutory_JJ income_NN statement_NN and_CC cash_NN flow_NN statement_NN for_IN the_DT period_NN from_IN 8_CD September_NNP 2005_CD ,_, the_DT date_NN of_IN incorporation_NN ,_, to_TO 31_CD December_NNP 2005_CD is_VBZ presented_VBN in_IN Note_NN 44_CD ,_, in_IN order_NN to_TO comply_VB with_IN Section_NN 226_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Significant_JJ accounting_NN policies_NNS Basis_NN of_IN accounting_NN Hikma_NNP Pharmaceuticals_NNP PLCs_NNP consolidated_JJ financial_JJ statements_NNS are_VBP prepared_VBN in_IN accordance_NN with_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP issued_VBN by_IN the_DT International_NNP Accounting_NNP Standards_NNP Board_NNP ._.
The_DT financial_JJ statements_NNS have_VBP also_RB been_VBN prepared_VBN in_IN accordance_NN with_IN IFRS_NNP adopted_VBD for_IN use_NN in_IN the_DT European_NNP Union_NNP and_CC therefore_RB comply_VB with_IN Article_NNP 4_CD of_IN the_DT EU_NNP IAS_NNP Regulation_NN ._.
The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN the_DT historical_JJ cost_NN convention_NN ,_, except_IN for_IN the_DT revaluation_NN to_TO market_NN of_IN certain_JJ financial_JJ assets_NNS and_CC liabilities_NNS ._.
The_DT Groups_NNS previously_RB published_VBN financial_JJ statements_NNS were_VBD also_RB prepared_VBN in_IN accordance_NN with_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS ._.
These_DT International_NNP Financial_NNP Reporting_NNP Standards_NNPS have_VBP been_VBN subject_JJ to_TO amendment_NN and_CC interpretation_NN by_IN the_DT International_NNP Accounting_NNP Standards_NNP Board_NNP and_CC the_DT financial_JJ statements_NNS presented_VBN for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2004_CD and_CC 31_CD December_NNP 2005_CD have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN those_DT revised_VBN standards_NNS ._.
Unless_IN stated_VBN otherwise_RB these_DT policies_NNS are_VBP in_IN accordance_NN with_IN the_DT revised_VBN standards_NNS that_WDT have_VBP been_VBN applied_VBN throughout_IN the_DT year_NN and_CC prior_JJ years_NNS presented_VBN in_IN this_DT financial_JJ statements_NNS ._.
The_DT currency_NN used_VBN in_IN the_DT preparation_NN of_IN the_DT accompanying_VBG consolidated_JJ financial_JJ statements_NNS is_VBZ the_DT US_NNP Dollar_NNP as_IN the_DT majority_NN of_IN the_DT Companys_NNPS business_NN is_VBZ conducted_VBN in_IN US_NNP Dollars_NNPS $_$ ._.
The_DT significant_JJ accounting_NN policies_NNS are_VBP set_VBN out_RP below_IN ._.
Restatement_NN of_IN prior_JJ year_NN income_NN statement_NN comparatives_VBZ The_DT following_JJ restatements_NNS had_VBD no_DT effect_NN on_IN the_DT profit_NN for_IN the_DT 2004_CD financial_JJ year_NN or_CC on_IN the_DT net_JJ assets_NNS of_IN the_DT Group_NNP at_IN 31_CD December_NNP 2004_CD ._.
For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD ,_, the_DT Groups_NNS share_NN of_IN results_NNS of_IN associates_NNS has_VBZ been_VBN included_VBN within_IN operating_NN profit_NN as_IN the_DT Directors_NNS consider_VBP these_DT activities_NNS to_TO be_VB operational_JJ activities_NNS and_CC the_DT 2004_CD comparative_JJ has_VBZ been_VBN restated_VBN ._.
Accordingly_RB ,_, management_NN fees_NNS receivable_JJ from_IN associates_NNS of_IN $_$ 1,016,000_CD 2004_CD :_: $_$ 333,000_CD are_VBP included_VBN in_IN other_JJ operating_NN income_NN ._.
In_IN 2004_CD the_DT management_NN fees_NNS were_VBD included_VBN in_IN other_JJ income_NN ._.
Flotation_NN costs_NNS totalling_VBG $_$ 425,000_CD incurred_VBN in_IN 2004_CD were_VBD classified_VBN as_IN general_JJ and_CC administrative_JJ expenses_NNS ._.
Following_VBG flotation_NN ,_, the_DT 2004_CD comparatives_NNS have_VBP been_VBN restated_VBN to_TO reflect_VB these_DT costs_NNS as_IN non_NN operational_JJ ._.
The_DT prior_JJ year_NN comparatives_NNS for_IN revenue_NN ,_, sales_NNS and_CC marketing_NN costs_NNS ,_, and_CC general_JJ and_CC administrative_JJ expenses_NNS have_VBP been_VBN restated_VBN to_TO reflect_VB a_DT change_NN in_IN accounting_NN policy_NN for_IN Medicaid_NNP rebates_NNS and_CC associated_VBN administrative_JJ charges_NNS paid_VBN to_TO the_DT wholesale_JJ customers_NNS of_IN the_DT Generics_NNP division_NN ._.
The_DT restatement_NN has_VBZ resulted_VBN in_IN revenue_NN ,_, sales_NNS and_CC marketing_NN costs_NNS ,_, and_CC general_JJ and_CC administrative_JJ expenses_NNS being_VBG decreased_VBN by_IN $_$ 1,771,000_CD ,_, $_$ 1,334,000_CD and_CC $_$ 437,000_CD respectively_RB ._.
This_DT restatement_NN had_VBD no_DT effect_NN on_IN operating_VBG profits_NNS for_IN the_DT period_NN ._.
Significant_JJ accounting_NN policies_NNS continued_VBD Basis_NN of_IN consolidation_NN The_DT consolidated_JJ financial_JJ statements_NNS incorporate_VBP the_DT results_NNS of_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP the_DT Company_NN and_CC entities_NNS controlled_VBN by_IN the_DT Company_NN together_RB the_DT Group_NNP ._.
Control_NNP is_VBZ achieved_VBN where_WRB the_DT Company_NN has_VBZ the_DT power_NN to_TO govern_VB the_DT financial_JJ and_CC operating_VBG policies_NNS of_IN an_DT investee_NN entity_NN so_RB as_IN to_TO obtain_VB benefits_NNS from_IN its_PRP$ activities_NNS ._.
On_IN acquisition_NN ,_, the_DT assets_NNS and_CC liabilities_NNS and_CC contingent_JJ liabilities_NNS of_IN a_DT subsidiary_NN are_VBP measured_VBN at_IN their_PRP$ fair_JJ values_NNS at_IN the_DT date_NN of_IN acquisition_NN ._.
Any_DT excess_NN of_IN the_DT cost_NN of_IN acquisition_NN over_IN the_DT fair_JJ values_NNS of_IN the_DT identifiable_JJ net_JJ assets_NNS acquired_VBN is_VBZ recognized_VBN as_IN goodwill_NN ._.
The_DT interest_NN of_IN minority_NN shareholders_NNS is_VBZ stated_VBN at_IN the_DT minoritys_NNS proportion_NN of_IN the_DT fair_JJ values_NNS of_IN the_DT assets_NNS and_CC liabilities_NNS recognized_VBN ._.
Subsequently_RB ,_, any_DT losses_NNS applicable_JJ to_TO the_DT minority_NN interest_NN in_IN excess_NN of_IN the_DT minority_NN interest_NN are_VBP allocated_VBN against_IN the_DT interests_NNS of_IN the_DT parent_NN ._.
The_DT results_NNS of_IN subsidiaries_NNS acquired_VBN or_CC disposed_VBN of_IN during_IN the_DT year_NN are_VBP included_VBN in_IN the_DT consolidated_JJ income_NN statement_NN from_IN the_DT effective_JJ date_NN of_IN acquisition_NN or_CC up_RB to_TO the_DT effective_JJ date_NN of_IN disposal_NN ,_, as_IN appropriate_JJ ._.
Where_WRB necessary_JJ ,_, adjustments_NNS are_VBP made_VBN to_TO the_DT financial_JJ statements_NNS of_IN subsidiaries_NNS to_TO bring_VB the_DT accounting_NN policies_NNS used_VBN in_IN line_NN with_IN those_DT used_VBN by_IN the_DT Group_NNP ._.
All_DT intra-Group_JJ transactions_NNS ,_, balances_NNS ,_, income_NN and_CC expenses_NNS are_VBP eliminated_VBN on_IN consolidation_NN ._.
Business_NNP combinations_NNS The_DT acquisition_NN of_IN subsidiaries_NNS is_VBZ accounted_VBN for_IN using_VBG the_DT purchase_NN method_NN ._.
The_DT cost_NN of_IN the_DT acquisition_NN is_VBZ measured_VBN at_IN the_DT aggregate_NN of_IN the_DT fair_JJ values_NNS ,_, at_IN the_DT date_NN of_IN exchange_NN ,_, of_IN assets_NNS given_VBN ,_, liabilities_NNS incurred_VBN or_CC assumed_VBN ,_, and_CC equity_NN instruments_NNS issued_VBN by_IN the_DT Group_NNP in_IN exchange_NN for_IN control_NN of_IN the_DT acquiree_NN ,_, plus_CC any_DT costs_NNS directly_RB attributable_JJ to_TO the_DT business_NN combination_NN ._.
The_DT acquirees_NNS identifiable_JJ assets_NNS ,_, liabilities_NNS and_CC contingent_JJ liabilities_NNS that_WDT meet_VBP the_DT conditions_NNS for_IN recognition_NN under_IN IFRS_NNP 3_CD are_VBP recognized_VBN at_IN their_PRP$ fair_JJ value_NN at_IN the_DT acquisition_NN date_NN ._.
Goodwill_NN arising_VBG on_IN acquisition_NN is_VBZ recognized_VBN as_IN an_DT asset_NN and_CC initially_RB measured_VBN at_IN cost_NN ,_, being_VBG the_DT excess_NN of_IN the_DT cost_NN of_IN the_DT business_NN combination_NN over_IN the_DT Groups_NNS interest_NN in_IN the_DT net_JJ fair_JJ value_NN of_IN the_DT identifiable_JJ assets_NNS ,_, liabilities_NNS and_CC contingent_JJ liabilities_NNS recognized_VBN ._.
If_IN ,_, after_IN reassessment_NN ,_, the_DT Groups_NNS interest_NN in_IN the_DT net_JJ fair_JJ value_NN of_IN the_DT acquirees_NNS identifiable_JJ assets_NNS ,_, liabilities_NNS and_CC contingent_JJ liabilities_NNS exceeds_VBZ the_DT cost_NN of_IN the_DT business_NN combination_NN ,_, the_DT excess_NN is_VBZ recognized_VBN immediately_RB in_IN profit_NN or_CC loss_NN ._.
The_DT interest_NN of_IN minority_NN shareholders_NNS in_IN the_DT acquiree_NN is_VBZ initially_RB measured_VBN at_IN the_DT minoritys_NNS proportion_NN of_IN the_DT net_JJ fair_JJ value_NN of_IN the_DT assets_NNS ,_, liabilities_NNS and_CC contingent_JJ liabilities_NNS recognized_VBN ._.
Investments_NNP in_IN associates_NNS An_DT associate_NN is_VBZ an_DT entity_NN over_IN which_WDT the_DT Group_NNP is_VBZ in_IN a_DT position_NN to_TO exercise_VB significant_JJ influence_NN ,_, but_CC not_RB control_VB or_CC joint_JJ control_NN ,_, through_IN participation_NN in_IN the_DT financial_JJ and_CC operating_NN policy_NN decisions_NNS of_IN the_DT investee_NN ._.
The_DT results_NNS and_CC assets_NNS and_CC liabilities_NNS of_IN associates_NNS are_VBP incorporated_VBN in_IN the_DT financial_JJ statements_NNS using_VBG the_DT equity_NN method_NN of_IN accounting_NN except_IN when_WRB classified_VBN as_IN held_VBN for_IN sale_NN ._.
Investments_NNP in_IN associates_NNS are_VBP carried_VBN in_IN the_DT balance_NN sheet_NN at_IN cost_NN as_IN adjusted_VBN by_IN post-acquisition_JJ changes_NNS in_IN the_DT Groups_NNS share_NN of_IN the_DT net_JJ assets_NNS of_IN the_DT associate_NN ,_, less_JJR any_DT impairment_NN in_IN the_DT value_NN of_IN individual_JJ investments_NNS ._.
Losses_NNS of_IN the_DT associates_NNS in_IN excess_NN of_IN the_DT Groups_NNS interest_NN in_IN those_DT associates_NNS are_VBP not_RB recognized_VBN ._.
Any_DT excess_NN of_IN the_DT cost_NN of_IN acquisition_NN over_IN the_DT Groups_NNS share_NN of_IN the_DT fair_JJ values_NNS of_IN the_DT identifiable_JJ net_JJ assets_NNS of_IN the_DT associate_NN at_IN the_DT date_NN of_IN acquisition_NN is_VBZ recognized_VBN as_IN goodwill_NN ._.
Where_WRB a_DT Group_NNP company_NN transacts_VBZ with_IN an_DT associate_NN of_IN the_DT Group_NNP ,_, profits_NNS and_CC losses_NNS are_VBP eliminated_VBN to_TO the_DT extent_NN of_IN the_DT Groups_NNS interest_NN in_IN the_DT relevant_JJ associate_NN ._.
52_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 2_CD ._.
Significant_JJ accounting_NN policies_NNS continued_VBD Intangible_JJ assets_NNS Intangible_JJ assets_NNS are_VBP valued_VBN at_IN cost_NN and_CC reviewed_VBN at_IN least_JJS annually_RB for_IN any_DT impairment_NN ._.
Any_DT resulting_VBG impairment_NN loss_NN is_VBZ recorded_VBN in_IN the_DT income_NN statement_NN under_IN general_JJ and_CC administrative_JJ expenses_NNS ._.
a_DT Goodwill_NNP :_: Goodwill_NNP arising_VBG on_IN consolidation_NN represents_VBZ the_DT excess_NN of_IN the_DT cost_NN of_IN acquisition_NN over_IN the_DT Groups_NNS interest_NN in_IN the_DT fair_JJ value_NN of_IN the_DT identifiable_JJ assets_NNS and_CC liabilities_NNS of_IN a_DT subsidiary_NN at_IN the_DT date_NN of_IN acquisition_NN ._.
Goodwill_NN is_VBZ initially_RB recognized_VBN as_IN an_DT asset_NN at_IN cost_NN and_CC is_VBZ subsequently_RB measured_VBN at_IN cost_NN less_JJR any_DT accumulated_VBN impairment_NN losses_NNS ._.
Goodwill_NN which_WDT is_VBZ recognized_VBN as_IN an_DT asset_NN is_VBZ reviewed_VBN for_IN impairment_NN at_IN least_JJS annually_RB ._.
Any_DT impairment_NN is_VBZ recognized_VBN immediately_RB in_IN profit_NN or_CC loss_NN and_CC is_VBZ not_RB subsequently_RB reversed_JJ ._.
For_IN the_DT purpose_NN of_IN impairment_NN testing_NN ,_, goodwill_NN is_VBZ allocated_VBN to_TO each_DT of_IN the_DT Groups_NNS cash-generating_JJ units_NNS ._.
Cash-generating_VBG units_NNS to_TO which_WDT goodwill_NN has_VBZ been_VBN allocated_VBN are_VBP tested_VBN for_IN impairment_NN annually_RB ,_, or_CC more_RBR frequently_RB when_WRB there_EX is_VBZ an_DT indication_NN that_IN the_DT unit_NN may_MD be_VB impaired_VBN ._.
If_IN the_DT recoverable_JJ amount_NN of_IN the_DT cash-generating_JJ unit_NN is_VBZ less_JJR than_IN the_DT carrying_VBG amount_NN of_IN the_DT unit_NN ,_, the_DT impairment_NN loss_NN is_VBZ allocated_VBN first_RB to_TO reduce_VB the_DT carrying_VBG amount_NN of_IN any_DT goodwill_NN allocated_VBN to_TO the_DT unit_NN and_CC then_RB to_TO the_DT other_JJ assets_NNS of_IN the_DT unit_NN pro_JJ rata_JJ on_IN the_DT basis_NN of_IN the_DT carrying_VBG amount_NN of_IN each_DT asset_NN in_IN the_DT unit_NN ._.
An_DT impairment_NN loss_NN recognized_VBN for_IN goodwill_NN is_VBZ not_RB reversed_VBN in_IN a_DT subsequent_JJ period_NN ._.
On_IN disposal_NN of_IN a_DT subsidiary_NN ,_, the_DT attributable_JJ amount_NN of_IN goodwill_NN is_VBZ included_VBN in_IN the_DT determination_NN of_IN the_DT profit_NN or_CC loss_NN on_IN disposal_NN ._.
b_NN Marketing_NNP rights_NNS :_: are_VBP amortised_VBN over_IN their_PRP$ useful_JJ lives_NNS commencing_VBG in_IN the_DT year_NN in_IN which_WDT the_DT rights_NNS first_RB generate_VBP sales_NNS ._.
c_NN Product_NNP files_NNS :_: product_NN files_NNS are_VBP assigned_VBN indefinite_JJ useful_JJ lives_NNS which_WDT are_VBP reviewed_VBN for_IN impairment_NN at_IN least_JJS annually_RB :_: any_DT impairment_NN is_VBZ recognized_VBN immediately_RB in_IN profit_NN and_CC loss_NN and_CC is_VBZ not_RB subsequently_RB reversed_JJ ._.
d_LS Purchased_VBN software_NN :_: is_VBZ amortised_VBN over_IN three_CD years_NNS ._.
Foreign_NNP currencies_NNS For_IN the_DT purpose_NN of_IN the_DT consolidated_JJ financial_JJ statements_NNS ,_, the_DT results_NNS and_CC financial_JJ position_NN of_IN each_DT Group_NNP company_NN are_VBP expressed_VBN in_IN US_NNP Dollars_NNPS ,_, which_WDT is_VBZ the_DT functional_JJ currency_NN of_IN the_DT Group_NNP ,_, and_CC the_DT presentation_NN currency_NN for_IN the_DT consolidated_JJ financial_JJ statements_NNS ._.
Transactions_NNS in_IN currencies_NNS other_JJ than_IN local_JJ currency_NN are_VBP recorded_VBN at_IN the_DT rates_NNS of_IN exchange_NN prevailing_VBG on_IN the_DT dates_NNS of_IN the_DT transactions_NNS ._.
At_IN each_DT balance_NN sheet_NN date_NN ,_, monetary_JJ assets_NNS and_CC liabilities_NNS that_WDT are_VBP denominated_VBN in_IN foreign_JJ currencies_NNS are_VBP retranslated_VBN at_IN the_DT rates_NNS prevailing_VBG on_IN the_DT balance_NN sheet_NN date_NN ._.
Non-monetary_JJ assets_NNS and_CC liabilities_NNS carried_VBD at_IN fair_JJ value_NN that_WDT are_VBP denominated_VBN in_IN foreign_JJ currencies_NNS are_VBP translated_VBN at_IN the_DT rates_NNS prevailing_VBG at_IN the_DT date_NN when_WRB the_DT fair_JJ value_NN was_VBD determined_VBN ._.
Non-monetary_JJ items_NNS that_WDT are_VBP measured_VBN in_IN terms_NNS of_IN historical_JJ cost_NN in_IN a_DT foreign_JJ currency_NN are_VBP not_RB retranslated_VBN ._.
Gains_NNS and_CC losses_NNS arising_VBG on_IN retranslation_NN are_VBP included_VBN in_IN net_JJ profit_NN or_CC loss_NN for_IN the_DT period_NN ,_, except_IN for_IN exchange_NN differences_NNS arising_VBG on_IN non-monetary_JJ assets_NNS and_CC liabilities_NNS where_WRB the_DT changes_NNS in_IN fair_JJ value_NN and_CC the_DT related_VBN foreign_JJ exchange_NN are_VBP recognized_VBN directly_RB in_IN equity_NN ._.
On_IN consolidation_NN ,_, the_DT assets_NNS and_CC liabilities_NNS of_IN the_DT Groups_NNS overseas_JJ operations_NNS are_VBP translated_VBN at_IN exchange_NN rates_NNS prevailing_VBG on_IN the_DT balance_NN sheet_NN date_NN ._.
Income_NN and_CC expense_NN items_NNS are_VBP translated_VBN at_IN the_DT average_JJ exchange_NN rates_NNS for_IN the_DT period_NN ._.
Exchange_NNP differences_NNS arising_VBG ,_, if_IN any_DT ,_, are_VBP classified_VBN as_IN equity_NN and_CC transferred_VBN to_TO the_DT Groups_NNS translation_NN reserve_NN ._.
Such_JJ cumulative_JJ translation_NN differences_NNS are_VBP recognized_VBN as_IN income_NN or_CC as_IN expenses_NNS in_IN the_DT period_NN in_IN which_WDT the_DT operation_NN is_VBZ disposed_VBN ._.
Revenue_NN recognition_NN Revenue_NN is_VBZ recognized_VBN in_IN the_DT income_NN statement_NN when_WRB goods_NNS or_CC services_NNS are_VBP supplied_VBN or_CC made_VBN available_JJ to_TO external_JJ customers_NNS against_IN orders_NNS received_VBN and_CC when_WRB title_NN and_CC risk_NN of_IN loss_NN passes_VBZ to_TO the_DT customer_NN ._.
Turnover_NN represents_VBZ net_JJ invoice_NN value_NN after_IN the_DT deduction_NN of_IN discounts_NNS and_CC allowances_NNS given_VBN and_CC accruals_NNS for_IN estimated_JJ future_JJ rebates_NNS and_CC returns_NNS ._.
The_DT methodology_NN and_CC assumptions_NNS used_VBN to_TO estimate_VB rebates_NNS and_CC returns_NNS are_VBP monitored_VBN and_CC adjusted_VBN regularly_RB in_IN the_DT light_NN of_IN contractual_JJ and_CC historical_JJ information_NN and_CC past_JJ experience_NN ._.
Value_NNP added_VBD tax_NN and_CC other_JJ sales_NNS taxes_NNS are_VBP excluded_VBN from_IN revenue_NN ._.
Significant_JJ accounting_NN policies_NNS continued_VBD Charge_NNP backs_VBZ The_DT provision_NN for_IN charge_NN backs_NNS is_VBZ the_DT most_RBS significant_JJ and_CC complex_JJ estimate_NN used_VBN in_IN the_DT recognition_NN of_IN revenue_NN ._.
In_IN the_DT USA_NNP the_DT Group_NNP sells_VBZ its_PRP$ products_NNS directly_RB to_TO wholesale_JJ distributors_NNS ,_, generic_JJ distributors_NNS ,_, retail_JJ pharmacy_NN chains_NNS and_CC mail-order_JJ pharmacies_NNS ._.
The_DT Group_NNP also_RB sells_VBZ its_PRP$ products_NNS indirectly_RB to_TO independent_JJ pharmacies_NNS ,_, managed_VBD care_NN organizations_NNS ,_, hospitals_NNS ,_, and_CC Group_NNP purchasing_VBG organizations_NNS ,_, collectively_RB referred_VBD to_TO as_IN indirect_JJ customers_NNS ._.
The_DT Group_NNP enters_VBZ into_IN agreements_NNS with_IN its_PRP$ indirect_JJ customers_NNS to_TO establish_VB pricing_NN for_IN certain_JJ products_NNS ._.
The_DT indirect_JJ customers_NNS then_RB independently_RB select_VB a_DT wholesaler_NN from_IN which_WDT they_PRP purchase_VBP the_DT products_NNS at_IN agreed-upon_JJ prices_NNS ._.
The_DT Group_NNP will_MD provide_VB credit_NN to_TO the_DT wholesaler_NN for_IN the_DT difference_NN between_IN the_DT agreed-upon_JJ price_NN with_IN the_DT indirect_JJ customer_NN and_CC the_DT wholesalers_NNS invoice_VBP price_NN ._.
This_DT credit_NN is_VBZ called_VBN a_DT charge_NN back_RB ._.
The_DT provision_NN for_IN charge_NN backs_NNS is_VBZ based_VBN on_IN historical_JJ sell-through_JJ levels_NNS by_IN the_DT Groups_NNS wholesale_JJ customers_NNS to_TO the_DT indirect_JJ customers_NNS ,_, and_CC estimated_VBD wholesaler_NN inventory_NN levels_NNS ._.
As_IN sales_NNS are_VBP made_VBN to_TO the_DT large_JJ wholesale_JJ customers_NNS ,_, the_DT Group_NNP continually_RB monitors_VBZ the_DT reserve_NN for_IN chargebacks_NNS and_CC makes_VBZ adjustments_NNS when_WRB it_PRP believes_VBZ that_IN actual_JJ charge_NN backs_NNS may_MD differ_VB from_IN estimated_VBN reserves_NNS ._.
Returns_NNS and_CC rebates_NNS In_IN certain_JJ countries_NNS and_CC consistent_JJ with_IN industry_NN practice_NN ,_, the_DT Group_NNP has_VBZ a_DT product_NN return_NN policy_NN that_WDT allows_VBZ selected_VBN customers_NNS to_TO return_VB the_DT product_NN within_IN a_DT specified_JJ period_NN prior_RB to_TO and_CC subsequent_JJ to_TO the_DT expiration_NN date_NN ,_, in_IN exchange_NN for_IN a_DT credit_NN to_TO be_VB applied_VBN to_TO future_JJ purchases_NNS ._.
The_DT Group_NNP estimates_VBZ its_PRP$ provision_NN for_IN returns_NNS and_CC rebates_NNS based_VBN on_IN historical_JJ experience_NN ,_, changes_NNS to_TO business_NN practices_NNS and_CC credit_NN terms_NNS ._.
While_IN such_JJ experience_NN has_VBZ allowed_VBN for_IN reasonable_JJ estimations_NNS in_IN the_DT past_NN ,_, history_NN may_MD not_RB always_RB be_VB an_DT accurate_JJ indicator_NN of_IN future_JJ returns_NNS ._.
The_DT Group_NNP continually_RB monitors_VBZ the_DT provisions_NNS for_IN returns_NNS and_CC rebates_NNS ,_, and_CC makes_VBZ adjustments_NNS when_WRB it_PRP believes_VBZ that_IN actual_JJ product_NN returns_NNS may_MD differ_VB from_IN established_VBN reserves_NNS ._.
Generally_RB ,_, the_DT reserve_NN for_IN returns_NNS and_CC rebates_NNS increases_NNS as_IN net_JJ sales_NNS increase_NN ._.
Price_NNP adjustments_NNS Price_NNP adjustments_NNS ,_, also_RB known_VBN as_IN shelf_NN stock_NN adjustments_NNS ,_, are_VBP credits_NNS issued_VBN to_TO reflect_VB decreases_VBZ in_IN the_DT selling_NN prices_NNS of_IN the_DT Groups_NNS products_NNS that_IN customers_NNS have_VBP remaining_VBG in_IN their_PRP$ inventories_NNS at_IN the_DT time_NN of_IN the_DT price_NN reduction_NN ._.
Decreases_NNS in_IN selling_VBG prices_NNS are_VBP discretionary_JJ decisions_NNS made_VBN by_IN Group_NNP management_NN to_TO reflect_VB competitive_JJ market_NN conditions_NNS ._.
Amounts_NNS recorded_VBD for_IN estimated_VBN shelf_NN stock_NN adjustments_NNS are_VBP based_VBN upon_IN specified_VBN terms_NNS with_IN direct_JJ customers_NNS ,_, estimated_VBN declines_NNS in_IN market_NN prices_NNS and_CC estimates_NNS of_IN inventory_NN held_VBN by_IN customers_NNS ._.
The_DT Group_NNP regularly_RB monitors_VBZ these_DT and_CC other_JJ factors_NNS and_CC re-evaluates_VBZ the_DT reserve_NN as_IN additional_JJ information_NN becomes_VBZ available_JJ ._.
Borrowing_NN costs_NNS Borrowing_VBG costs_NNS directly_RB attributable_JJ to_TO the_DT acquisition_NN ,_, construction_NN or_CC production_NN of_IN qualifying_VBG assets_NNS ,_, which_WDT are_VBP assets_NNS that_WDT necessarily_RB take_VB a_DT substantial_JJ period_NN of_IN time_NN to_TO get_VB ready_JJ for_IN their_PRP$ intended_VBN use_NN or_CC sale_NN ,_, are_VBP added_VBN to_TO the_DT cost_NN of_IN those_DT assets_NNS ,_, until_IN such_JJ time_NN as_IN the_DT assets_NNS are_VBP substantially_RB ready_JJ for_IN their_PRP$ intended_VBN use_NN or_CC sale_NN ._.
Investment_NN income_NN earned_VBN on_IN the_DT temporary_JJ investment_NN of_IN specific_JJ borrowings_NNS pending_VBG their_PRP$ expenditure_NN on_IN qualifying_VBG assets_NNS is_VBZ deducted_VBN from_IN the_DT borrowing_NN costs_VBZ eligible_JJ for_IN capitalization_NN ._.
All_DT other_JJ borrowing_NN costs_NNS are_VBP recognized_VBN in_IN profit_NN or_CC loss_NN in_IN the_DT period_NN in_IN which_WDT they_PRP are_VBP incurred_VBN ._.
Dividend_NN income_NN Income_NN from_IN investments_NNS is_VBZ recognized_VBN when_WRB the_DT shareholders_NNS rights_NNS to_TO receive_VB payment_NN have_VBP been_VBN established_VBN ._.
Leasing_NNP Leases_NNPS are_VBP classified_VBN as_IN capital_NN leases_NNS whenever_WRB the_DT terms_NNS of_IN the_DT lease_NN transfer_NN substantially_RB all_PDT the_DT risks_NNS and_CC rewards_NNS of_IN ownership_NN to_TO the_DT lessee_NN ._.
All_DT other_JJ leases_NNS are_VBP classified_VBN as_IN operating_VBG leases_NNS ._.
Rentals_NNS payable_JJ under_IN operating_VBG leases_NNS are_VBP charged_VBN to_TO income_NN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT term_NN of_IN the_DT operating_NN lease_NN ._.
Assets_NNS held_VBN under_IN capital_NN leases_NNS are_VBP recognized_VBN as_IN assets_NNS of_IN the_DT Group_NNP at_IN their_PRP$ fair_JJ value_NN or_CC ,_, if_IN lower_JJR ,_, at_IN the_DT present_JJ value_NN of_IN the_DT minimum_NN lease_NN payments_NNS ,_, each_DT determined_VBN at_IN the_DT inception_NN of_IN the_DT lease_NN ._.
The_DT corresponding_JJ liability_NN to_TO the_DT lessor_NN is_VBZ included_VBN in_IN the_DT balance_NN sheet_NN as_IN a_DT capital_NN lease_NN obligation_NN ._.
Lease_NNP payments_NNS are_VBP apportioned_VBN between_IN finance_NN charges_NNS and_CC reduction_NN of_IN the_DT lease_NN obligation_NN so_RB as_IN to_TO achieve_VB a_DT constant_JJ rate_NN of_IN interest_NN on_IN the_DT remaining_VBG balance_NN of_IN the_DT liability_NN ._.
54_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 2_CD ._.
Significant_JJ accounting_NN policies_NNS continued_VBD Government_NNP grants_NNS Government_NNP grants_NNS relating_VBG to_TO property_NN ,_, plant_NN and_CC equipment_NN are_VBP treated_VBN as_IN deferred_JJ income_NN and_CC released_VBN to_TO the_DT income_NN statement_NN over_IN the_DT expected_VBN useful_JJ lives_NNS of_IN the_DT assets_NNS concerned_VBN ._.
Research_NNP and_CC development_NN Research_NN and_CC development_NN expenses_NNS are_VBP fully_RB charged_VBN to_TO the_DT income_NN statement_NN ,_, as_IN the_DT Group_NNP considers_VBZ that_IN the_DT regulatory_JJ and_CC other_JJ uncertainties_NNS inherent_JJ in_IN the_DT development_NN of_IN its_PRP$ products_NNS generally_RB mean_VBP that_IN the_DT recognition_NN criteria_NNS in_IN IAS_NNP 38_CD Intangible_JJ assets_NNS are_VBP not_RB met_VBN ._.
Where_WRB ,_, however_RB the_DT recognition_NN criteria_NNS are_VBP met_VBN ,_, intangible_JJ assets_NNS will_MD be_VB capitalized_VBN and_CC amortised_VBN over_IN their_PRP$ useful_JJ economic_JJ life_NN ._.
Retirement_NNP benefit_NN costs_NNS Payments_NNS to_TO defined_VBN contribution_NN retirement_NN benefit_NN schemes_NNS are_VBP charged_VBN as_IN an_DT expense_NN as_IN they_PRP fall_VBP due_JJ ._.
Payments_NNS made_VBD to_TO state-managed_JJ retirement_NN benefit_NN schemes_NNS are_VBP dealt_VBN with_IN as_IN payments_NNS to_TO defined_VBN contribution_NN schemes_NNS where_WRB the_DT Groups_NNS obligations_NNS under_IN the_DT schemes_NNS are_VBP equivalent_JJ to_TO those_DT arising_VBG in_IN a_DT defined_VBN contribution_NN retirement_NN benefit_NN scheme_NN ._.
Tax_NNP The_NNP Group_NNP provides_VBZ for_IN income_NN tax_NN according_VBG to_TO the_DT laws_NNS and_CC regulations_NNS prevailing_VBG in_IN the_DT countries_NNS where_WRB the_DT Group_NNP operates_VBZ ._.
Furthermore_RB ,_, the_DT Group_NNP computes_NNS and_CC records_NNS deferred_VBN tax_NN assets_NNS according_VBG to_TO IAS_NNP 12_CD Income_NNP Taxes_NNS ._.
The_DT tax_NN expense_NN represents_VBZ the_DT sum_NN of_IN the_DT tax_NN currently_RB payable_JJ and_CC deferred_JJ tax_NN ._.
The_DT tax_NN currently_RB payable_JJ is_VBZ based_VBN on_IN taxable_JJ profit_NN for_IN the_DT year_NN ._.
Taxable_JJ profit_NN differs_VBZ from_IN net_JJ profit_NN as_IN reported_VBN in_IN the_DT income_NN statements_NNS because_IN it_PRP excludes_VBZ items_NNS of_IN income_NN or_CC expense_NN that_WDT are_VBP taxable_JJ or_CC deductible_JJ in_IN other_JJ years_NNS and_CC it_PRP further_RB excludes_VBZ items_NNS that_WDT are_VBP never_RB taxable_JJ or_CC deductible_JJ ._.
The_DT Groups_NNS liability_NN for_IN current_JJ tax_NN is_VBZ calculated_VBN using_VBG tax_NN rates_NNS that_WDT have_VBP been_VBN enacted_VBN or_CC substantively_RB enacted_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
Deferred_JJ tax_NN is_VBZ the_DT tax_NN expected_VBN to_TO be_VB payable_JJ or_CC recoverable_JJ on_IN differences_NNS between_IN the_DT carrying_VBG amounts_NNS of_IN assets_NNS and_CC liabilities_NNS in_IN the_DT financial_JJ statements_NNS and_CC the_DT corresponding_JJ tax_NN bases_NNS used_VBN in_IN the_DT computation_NN of_IN taxable_JJ profit_NN ,_, and_CC is_VBZ accounted_VBN for_IN using_VBG the_DT balance_NN sheet_NN liability_NN method_NN ._.
Deferred_JJ tax_NN liabilities_NNS are_VBP generally_RB recognized_VBN for_IN all_DT taxable_JJ temporary_JJ differences_NNS and_CC deferred_VBN tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ probable_JJ that_IN taxable_JJ profits_NNS will_MD be_VB available_JJ against_IN which_WDT deductible_JJ temporary_JJ differences_NNS can_MD be_VB utilised_VBN ._.
Such_JJ assets_NNS and_CC liabilities_NNS are_VBP not_RB recognized_VBN if_IN the_DT temporary_JJ difference_NN arises_VBZ from_IN goodwill_NN or_CC from_IN the_DT initial_JJ recognition_NN other_JJ than_IN in_IN a_DT business_NN combination_NN of_IN other_JJ assets_NNS and_CC liabilities_NNS in_IN a_DT transaction_NN that_WDT affects_VBZ neither_CC the_DT tax_NN profit_NN nor_CC the_DT accounting_NN profit_NN ._.
Deferred_JJ tax_NN liabilities_NNS are_VBP recognized_VBN for_IN taxable_JJ temporary_JJ differences_NNS arising_VBG on_IN investments_NNS in_IN subsidiaries_NNS and_CC associates_NNS ,_, and_CC interests_NNS in_IN joint_JJ ventures_NNS ,_, except_IN where_WRB the_DT Group_NNP is_VBZ able_JJ to_TO control_VB the_DT reversal_NN of_IN the_DT temporary_JJ difference_NN and_CC it_PRP is_VBZ probable_JJ that_IN the_DT temporary_JJ difference_NN will_MD not_RB reverse_VB in_IN the_DT foreseeable_JJ future_NN ._.
The_DT carrying_VBG amount_NN of_IN deferred_JJ tax_NN assets_NNS is_VBZ reviewed_VBN at_IN each_DT balance_NN sheet_NN date_NN and_CC reduced_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ no_RB longer_RB probable_JJ that_IN sufficient_JJ taxable_JJ profits_NNS will_MD be_VB available_JJ to_TO allow_VB all_DT or_CC part_NN of_IN the_DT asset_NN to_TO be_VB recovered_VBN ._.
Deferred_JJ tax_NN is_VBZ calculated_VBN at_IN the_DT tax_NN rates_NNS that_WDT are_VBP expected_VBN to_TO apply_VB in_IN the_DT period_NN when_WRB the_DT liability_NN is_VBZ settled_VBN or_CC the_DT asset_NN is_VBZ realized_VBN ._.
Deferred_JJ tax_NN is_VBZ charged_VBN or_CC credited_VBN in_IN the_DT income_NN statement_NN ,_, except_IN when_WRB it_PRP relates_VBZ to_TO items_NNS charged_VBN or_CC credited_VBN directly_RB to_TO equity_NN ,_, in_IN which_WDT case_NN the_DT deferred_JJ tax_NN is_VBZ also_RB dealt_VBN with_IN in_IN equity_NN ._.
Share-based_JJ payment_NN transactions_NNS Employees_NNS including_VBG Directors_NNS of_IN the_DT Group_NNP receive_VBP remuneration_NN in_IN the_DT form_NN of_IN share-based_JJ payments_NNS ,_, whereby_WRB employees_NNS render_VB services_NNS in_IN exchange_NN for_IN shares_NNS or_CC rights_NNS over_IN shares_NNS equity-settled_JJ transactions_NNS ._.
Significant_JJ accounting_NN policies_NNS continued_VBD Equity-settled_JJ transactions_NNS The_DT cost_NN of_IN equity-settled_JJ transactions_NNS with_IN employees_NNS is_VBZ measured_VBN by_IN reference_NN to_TO the_DT fair_JJ value_NN at_IN the_DT date_NN at_IN which_WDT the_DT share-based_JJ payments_NNS are_VBP granted_VBN ._.
The_DT fair_JJ value_NN is_VBZ determined_VBN using_VBG a_DT binomial_JJ model_NN ._.
The_DT expected_VBN life_NN used_VBN in_IN the_DT model_NN has_VBZ been_VBN adjusted_VBN ,_, based_VBN on_IN managements_NNS best_JJS estimate_NN ,_, for_IN the_DT effects_NNS of_IN non-transferability_NN ,_, exercise_NN restrictions_NNS ,_, and_CC behavioural_JJ considerations_NNS further_RBR details_NNS are_VBP given_VBN in_IN Note_NN 36_CD ._.
In_IN valuing_VBG equity-settled_JJ transactions_NNS ,_, no_DT account_NN is_VBZ taken_VBN of_IN any_DT performance_NN conditions_NNS ,_, other_JJ than_IN conditions_NNS linked_VBN to_TO the_DT market_NN price_NN of_IN the_DT shares_NNS of_IN Hikma_NNP Pharmaceuticals_NNP PLC._NNP ._.
The_DT cost_NN of_IN equity-settled_JJ transactions_NNS is_VBZ recognized_VBN ,_, together_RB with_IN a_DT corresponding_JJ increase_NN in_IN equity_NN ,_, on_IN a_DT straight-line_JJ basis_NN over_IN the_DT vesting_JJ period_NN based_VBN on_IN the_DT Groups_NNS estimate_NN of_IN shares_NNS that_WDT will_MD eventually_RB vest_NN ._.
No_DT expense_NN is_VBZ recognized_VBN for_IN awards_NNS that_WDT do_VBP not_RB ultimately_RB vest_NN ._.
Where_WRB the_DT terms_NNS of_IN an_DT equity-settled_JJ award_NN are_VBP modified_VBN ,_, as_IN a_DT minimum_NN an_DT expense_NN is_VBZ recognized_VBN as_IN if_IN the_DT terms_NNS had_VBD not_RB been_VBN modified_VBN ._.
In_IN addition_NN ,_, an_DT expense_NN is_VBZ recognized_VBN for_IN any_DT increase_NN in_IN the_DT value_NN of_IN the_DT transaction_NN as_IN a_DT result_NN of_IN the_DT modification_NN ,_, as_IN measured_VBN at_IN the_DT modification_NN date_NN ._.
Where_WRB an_DT equity-settled_JJ award_NN is_VBZ canceled_VBN ,_, it_PRP is_VBZ treated_VBN as_IN if_IN it_PRP had_VBD vested_VBN on_IN the_DT date_NN of_IN cancellation_NN ,_, and_CC any_DT expense_NN not_RB yet_RB recognized_VBN for_IN the_DT award_NN is_VBZ recognized_VBN immediately_RB ._.
However_RB ,_, if_IN a_DT new_JJ award_NN is_VBZ substituted_VBN for_IN a_DT canceled_VBN award_NN ,_, and_CC designated_VBN as_IN a_DT replacement_NN award_NN on_IN the_DT date_NN that_IN it_PRP is_VBZ granted_VBN ,_, the_DT canceled_VBN and_CC new_JJ awards_NNS are_VBP treated_VBN as_IN if_IN they_PRP were_VBD a_DT modification_NN of_IN the_DT original_JJ award_NN ,_, as_IN described_VBN in_IN the_DT previous_JJ paragraph_NN ._.
The_DT dilutive_JJ effect_NN of_IN outstanding_JJ options_NNS is_VBZ reflected_VBN as_IN additional_JJ share_NN dilution_NN in_IN the_DT computation_NN of_IN diluted_JJ earnings_NNS per_IN share_NN ._.
IFRS_NNS 2_CD Share-based_JJ Payment_NN requires_VBZ an_DT expense_NN to_TO be_VB recognized_VBN when_WRB the_DT Group_NNP buys_VBZ goods_NNS or_CC services_NNS in_IN exchange_NN for_IN share_NN or_CC rights_NNS over_IN shares_NNS equity-settled_JJ transactions_NNS or_CC in_IN exchange_NN for_IN other_JJ equivalent_JJ assets_NNS ._.
Property_NN ,_, plant_NN and_CC equipment_NN Property_NN ,_, plant_NN and_CC equipment_NN have_VBP been_VBN valued_VBN at_IN cost_NN of_IN acquisition_NN and_CC are_VBP depreciated_VBN ,_, except_IN for_IN land_NN ,_, on_IN a_DT straight-line_JJ basis_NN at_IN the_DT following_VBG depreciation_NN rates_NNS :_: Buildings_NNS 2_CD %_NN to_TO 4_CD %_NN Vehicles_NNPS 10_CD %_NN to_TO 20_CD %_NN Machinery_NNP and_CC equipment_NN 5_CD %_NN to_TO 20_CD %_NN Fixtures_NNS and_CC equipment_NN 8_CD %_NN to_TO 33_CD %_NN Any_DT additional_JJ costs_NNS that_WDT extend_VBP the_DT useful_JJ life_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN are_VBP capitalized_VBN ._.
Financing_NN costs_NNS associated_VBN with_IN the_DT construction_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN are_VBP not_RB capitalized_VBN ._.
Property_NN ,_, plant_NN and_CC equipment_NN which_WDT are_VBP financed_VBN by_IN leases_NNS giving_VBG Hikma_NNP Pharmaceuticals_NNP PLC_NNP substantially_RB all_PDT the_DT risks_NNS and_CC rewards_NNS of_IN ownership_NN are_VBP capitalized_VBN at_IN the_DT lower_JJR of_IN the_DT fair_JJ value_NN of_IN leased_VBN property_NN and_CC the_DT present_JJ value_NN of_IN the_DT minimum_NN lease_NN payments_NNS at_IN the_DT inception_NN of_IN the_DT lease_NN ,_, and_CC depreciated_VBD in_IN the_DT same_JJ manner_NN as_IN other_JJ property_NN ,_, plant_NN and_CC equipment_NN over_IN the_DT shorter_JJR of_IN the_DT lease_NN term_NN or_CC their_PRP$ useful_JJ life_NN ._.
Whenever_NNP the_DT recoverable_JJ amount_NN of_IN an_DT asset_NN is_VBZ impaired_VBN ,_, the_DT carrying_VBG value_NN is_VBZ reduced_VBN to_TO the_DT recoverable_JJ amount_NN and_CC the_DT impairment_NN loss_NN is_VBZ taken_VBN to_TO the_DT income_NN statement_NN ._.
Projects_NNS under_IN construction_NN are_VBP carried_VBN at_IN cost_NN ,_, less_JJR any_DT recognized_VBN impairment_NN loss_NN ._.
Depreciation_NN of_IN these_DT assets_NNS ,_, on_IN the_DT same_JJ basis_NN as_IN other_JJ property_NN assets_NNS ,_, commences_NNS when_WRB the_DT assets_NNS are_VBP ready_JJ for_IN their_PRP$ intended_VBN use_NN ._.
The_DT gain_NN or_CC loss_NN arising_VBG on_IN the_DT disposal_NN or_CC retirement_NN of_IN an_DT asset_NN is_VBZ determined_VBN as_IN the_DT difference_NN between_IN the_DT sales_NNS proceeds_NNS and_CC the_DT carrying_VBG amount_NN of_IN the_DT asset_NN and_CC is_VBZ recognized_VBN in_IN the_DT income_NN statement_NN ._.
Inventories_NNS Inventories_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Purchased_JJ products_NNS are_VBP valued_VBN at_IN acquisition_NN cost_NN and_CC all_DT other_JJ costs_NNS incurred_VBN in_IN bringing_VBG each_DT product_NN to_TO its_PRP$ present_JJ location_NN and_CC condition_NN ._.
Cost_NN of_IN own-manufactured_JJ products_NNS comprises_VBZ direct_JJ materials_NNS and_CC ,_, where_WRB applicable_JJ ,_, direct_JJ labor_NN costs_NNS and_CC those_DT overheads_NNS that_WDT have_VBP been_VBN incurred_VBN in_IN bringing_VBG the_DT inventories_NNS to_TO their_PRP$ present_JJ location_NN and_CC condition_NN ._.
In_IN the_DT balance_NN sheets_NNS ,_, inventory_NN is_VBZ primarily_RB valued_VBN at_IN standard_JJ cost_NN ,_, which_WDT approximates_VBZ to_TO historical_JJ cost_NN determined_VBN on_IN a_DT moving_VBG average_JJ basis_NN ,_, and_CC this_DT value_NN is_VBZ used_VBN to_TO determine_VB the_DT cost_NN of_IN sales_NNS in_IN the_DT income_NN statement_NN ._.
Net_JJ realisable_JJ value_NN represents_VBZ the_DT estimated_VBN selling_NN price_NN in_IN the_DT ordinary_JJ course_NN of_IN business_NN ,_, less_JJR all_DT estimated_VBN costs_NNS of_IN completion_NN and_CC all_DT estimated_VBN costs_NNS necessary_JJ to_TO make_VB the_DT sale_NN ._.
Provisions_NNS are_VBP made_VBN for_IN inventories_NNS with_IN net_JJ realisable_JJ value_NN lower_JJR than_IN cost_NN or_CC for_IN slow_JJ moving_VBG inventory_NN ._.
56_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 2_CD ._.
Significant_JJ accounting_NN policies_NNS continued_VBD Financial_JJ instruments_NNS Financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS are_VBP recognized_VBN on_IN the_DT Groups_NNS balance_NN sheet_NN when_WRB the_DT Group_NNP becomes_VBZ a_DT party_NN to_TO the_DT contractual_JJ provisions_NNS of_IN the_DT instrument_NN ._.
Derivative_JJ financial_JJ instruments_NNS are_VBP used_VBN to_TO manage_VB exposure_NN to_TO market_NN risks_NNS from_IN treasury_NN operations_NNS ._.
The_DT principal_JJ derivative_NN instruments_NNS used_VBN by_IN the_DT Group_NNP are_VBP interest_NN rate_NN swaps_NNS and_CC forward_RB foreign_JJ exchange_NN contracts_NNS ._.
The_DT Group_NNP does_VBZ not_RB hold_VB or_CC issue_VB derivative_JJ financial_JJ instruments_NNS for_IN trading_NN or_CC speculative_JJ purposes_NNS ._.
Derivative_JJ financial_JJ instruments_NNS are_VBP initially_RB recognized_VBN in_IN the_DT balance_NN sheet_NN at_IN cost_NN and_CC then_RB remeasured_VBD at_IN subsequent_JJ reporting_NN dates_NNS to_TO fair_JJ value_NN ._.
Hedging_VBG derivatives_NNS are_VBP classified_VBN on_IN inception_NN as_IN fair_JJ value_NN hedges_NNS ,_, cash_NN flow_NN hedges_NNS or_CC net_JJ investment_NN hedges_NNS ._.
Changes_NNS in_IN the_DT fair_JJ value_NN of_IN derivatives_NNS designed_VBN as_IN fair_JJ value_NN hedges_NNS are_VBP recorded_VBN in_IN the_DT income_NN statement_NN ,_, with_IN the_DT changes_NNS in_IN the_DT fair_JJ value_NN of_IN the_DT hedged_JJ asset_NN or_CC liability_NN ._.
Changes_NNS in_IN the_DT fair_JJ value_NN of_IN derivatives_NNS designed_VBN as_IN cash_NN flow_NN hedges_NNS are_VBP recognized_VBN in_IN equity_NN ._.
Amounts_NNS deferred_VBN in_IN equity_NN are_VBP transferred_VBN to_TO the_DT income_NN statement_NN in_IN line_NN with_IN the_DT hedged_VBN forecast_NN transaction_NN ._.
Hedges_NNP of_IN net_JJ investments_NNS in_IN foreign_JJ entities_NNS are_VBP accounted_VBN for_IN in_IN a_DT similar_JJ way_NN to_TO cash_NN flow_NN hedges_NNS ._.
Changes_NNS in_IN the_DT fair_JJ value_NN of_IN any_DT derivative_JJ instruments_NNS that_WDT do_VBP not_RB qualify_VB for_IN hedge_JJ accounting_NN are_VBP recognized_VBN immediately_RB in_IN the_DT income_NN statement_NN ._.
Investments_NNP Available_NNP for_IN sale_NN investments_NNS with_IN quoted_VBN market_NN prices_NNS are_VBP initially_RB recognized_VBN at_IN cost_NN on_IN acquisition_NN and_CC remeasured_VBD to_TO their_PRP$ fair_JJ values_NNS at_IN year-end_NN ._.
Gains_NNS or_CC losses_NNS on_IN remeasurement_NN to_TO fair_JJ value_NN are_VBP recognized_VBN in_IN shareholders_NNS equity_NN until_IN the_DT investments_NNS are_VBP sold_VBN ,_, disposed_VBN of_IN ,_, or_CC determined_VBN to_TO be_VB impaired_VBN ,_, at_IN which_WDT time_NN the_DT cumulative_JJ gains_NNS or_CC loss_NN relating_VBG to_TO these_DT investments_NNS previously_RB recognized_VBN in_IN equity_NN is_VBZ included_VBN in_IN the_DT income_NN statement_NN ._.
Available_JJ for_IN sale_NN financial_JJ assets_NNS without_IN market_NN prices_NNS and_CC the_DT fair_JJ value_NN of_IN which_WDT can_MD not_RB be_VB reliably_RB measured_VBN are_VBP stated_VBN at_IN cost_NN ,_, less_JJR a_DT provision_NN for_IN any_DT impairment_NN loss_NN ,_, which_WDT is_VBZ taken_VBN to_TO the_DT income_NN statement_NN ._.
The_DT fair_JJ value_NN of_IN quoted_VBN financial_JJ assets_NNS represents_VBZ the_DT closing_NN price_NN in_IN the_DT financial_JJ markets_NNS at_IN the_DT date_NN of_IN the_DT financial_JJ statements_NNS ._.
However_RB ,_, the_DT fair_JJ value_NN of_IN unquoted_JJ financial_JJ assets_NNS ,_, or_CC those_DT with_IN no_DT declared_VBN price_NN are_VBP estimated_VBN by_IN comparing_VBG the_DT fair_JJ value_NN of_IN a_DT similar_JJ financial_JJ instrument_NN or_CC through_IN a_DT discounted_JJ cash_NN flow_NN method_NN ._.
Accounts_NNPS receivable_JJ Trade_NNP receivables_NNS are_VBP measured_VBN at_IN initial_JJ recognition_NN at_IN fair_JJ value_NN ,_, and_CC are_VBP subsequently_RB measured_VBN at_IN amortised_JJ cost_NN using_VBG the_DT effective_JJ interest_NN rate_NN method_NN ._.
Appropriate_JJ allowances_NNS for_IN estimated_VBN irrecoverable_JJ amounts_NNS are_VBP recognized_VBN in_IN profit_NN or_CC loss_NN when_WRB there_EX is_VBZ objective_JJ evidence_NN that_IN the_DT asset_NN is_VBZ impaired_VBN ._.
The_DT allowance_NN recognized_VBN is_VBZ measured_VBN as_IN the_DT difference_NN between_IN the_DT assets_NNS carrying_VBG amount_NN and_CC the_DT present_JJ value_NN of_IN estimated_JJ future_JJ cash_NN flows_VBZ discounted_VBN at_IN the_DT effective_JJ interest_NN rate_NN computed_VBD at_IN initial_JJ recognition_NN ._.
Cash_NN and_CC cash_NN equivalents_NNS Cash_NN and_CC cash_NN equivalents_NNS include_VBP highly_RB liquid_JJ investments_NNS with_IN original_JJ maturities_NNS of_IN three_CD months_NNS or_CC less_JJR and_CC are_VBP subject_JJ to_TO an_DT insignificant_JJ risk_NN of_IN changes_NNS in_IN value_NN ._.
Bank_NNP borrowings_NNS Interest-bearing_JJ bank_NN loans_NNS and_CC overdrafts_NNS are_VBP recorded_VBN at_IN the_DT proceeds_NNS received_VBD ,_, net_NN of_IN direct_JJ issue_NN costs_NNS ._.
Finance_NNP charges_NNS ,_, including_VBG premiums_NNS payable_JJ on_IN settlement_NN or_CC redemption_NN and_CC direct_JJ issue_NN costs_NNS ,_, are_VBP accounted_VBN for_IN on_IN an_DT accrual_NN basis_NN in_IN profit_NN or_CC loss_NN account_NN using_VBG the_DT effective_JJ interest_NN method_NN and_CC are_VBP added_VBN to_TO the_DT carrying_VBG amount_NN of_IN the_DT instrument_NN to_TO the_DT extent_NN that_IN they_PRP are_VBP not_RB settled_VBN in_IN the_DT period_NN in_IN which_WDT they_PRP arise_VBP ._.
Trade_NNP payables_NNS Trade_NNP payables_NNS are_VBP not_RB interest_NN bearing_NN and_CC are_VBP stated_VBN at_IN fair_JJ value_NN ._.
Equity_NN instruments_NNS Equity_NN instruments_NNS issued_VBN by_IN the_DT Group_NNP are_VBP recorded_VBN at_IN the_DT proceeds_NNS received_VBD ,_, net_NN of_IN direct_JJ issue_NN costs_NNS ._.
Significant_JJ accounting_NN policies_NNS continued_VBD Provisions_NNP Provisions_NNS are_VBP recognized_VBN when_WRB the_DT Group_NNP has_VBZ a_DT present_JJ obligation_NN legal_JJ or_CC constructive_JJ as_IN a_DT result_NN of_IN a_DT past_JJ event_NN ,_, it_PRP is_VBZ probable_JJ that_IN an_DT outflow_NN of_IN resources_NNS embodying_VBG economic_JJ benefits_NNS will_MD be_VB required_VBN to_TO settle_VB the_DT obligation_NN and_CC a_DT reliable_JJ estimate_NN can_MD be_VB made_VBN of_IN the_DT amount_NN of_IN the_DT obligation_NN ._.
Impairment_NN of_IN tangible_JJ and_CC intangible_JJ assets_NNS excluding_VBG goodwill_NN At_IN each_DT balance_NN sheet_NN date_NN ,_, the_DT Group_NNP reviews_VBZ the_DT carrying_VBG amounts_NNS of_IN its_PRP$ tangible_JJ and_CC intangible_JJ assets_NNS to_TO determine_VB whether_IN there_EX is_VBZ any_DT indication_NN that_IN those_DT assets_NNS have_VBP suffered_VBN an_DT impairment_NN loss_NN ._.
If_IN any_DT such_JJ indication_NN exists_VBZ ,_, the_DT recoverable_JJ amount_NN of_IN the_DT asset_NN is_VBZ estimated_VBN in_IN order_NN to_TO determine_VB the_DT extent_NN of_IN the_DT impairment_NN loss_NN ._.
An_DT intangible_JJ asset_NN with_IN an_DT indefinite_JJ useful_JJ life_NN is_VBZ tested_VBN for_IN impairment_NN annually_RB and_CC whenever_WRB there_EX is_VBZ an_DT indication_NN that_IN the_DT asset_NN may_MD be_VB impaired_VBN ._.
Recoverable_JJ amount_NN is_VBZ the_DT higher_JJR of_IN fair_JJ value_NN less_RBR costs_NNS to_TO sell_VB and_CC value_NN in_IN use_NN ._.
In_IN assessing_VBG value_NN in_IN use_NN ,_, the_DT estimated_JJ future_JJ cash_NN flows_NNS are_VBP discounted_VBN to_TO their_PRP$ present_JJ value_NN using_VBG a_DT pre-tax_JJ discount_NN rate_NN that_WDT reflects_VBZ current_JJ market_NN assessments_NNS of_IN the_DT time_NN value_NN of_IN money_NN and_CC the_DT risks_NNS specific_JJ to_TO the_DT asset_NN for_IN which_WDT the_DT estimates_NNS of_IN future_JJ cash_NN flows_NNS have_VBP not_RB been_VBN adjusted_VBN ._.
If_IN the_DT recoverable_JJ amount_NN of_IN an_DT asset_NN or_CC income-generating_JJ unit_NN is_VBZ estimated_VBN to_TO be_VB less_JJR than_IN its_PRP$ carrying_VBG amount_NN ,_, the_DT carrying_VBG amount_NN of_IN the_DT asset_NN income-generating_JJ unit_NN is_VBZ reduced_VBN to_TO its_PRP$ recoverable_JJ amount_NN ._.
An_DT impairment_NN loss_NN is_VBZ recognized_VBN as_IN an_DT expense_NN immediately_RB ._.
Where_WRB an_DT impairment_NN loss_NN subsequently_RB reverses_VBZ ,_, the_DT carrying_VBG amount_NN of_IN the_DT asset_NN cash-generating_JJ unit_NN is_VBZ increased_VBN to_TO the_DT revised_VBN estimate_NN of_IN its_PRP$ recoverable_JJ amount_NN ,_, but_CC so_RB that_IN the_DT increased_VBN carrying_VBG amount_NN does_VBZ not_RB exceed_VB the_DT carrying_VBG amount_NN that_WDT would_MD have_VB been_VBN determined_VBN had_VBD no_DT impairment_NN loss_NN been_VBN recognized_VBN for_IN the_DT asset_NN cash-generating_JJ unit_NN in_IN prior_JJ years_NNS ._.
A_DT reversal_NN of_IN an_DT impairment_NN loss_NN is_VBZ recognized_VBN as_IN income_NN immediately_RB ._.
New_NNP accounting_NN policies_NNS and_CC future_JJ requirements_NNS The_DT following_JJ IFRS_NNP and_CC IFRIC_NNP interpretation_NN have_VBP been_VBN issued_VBN by_IN the_DT IASB_NNP and_CC are_VBP likely_JJ to_TO affect_VB future_JJ annual_JJ reports_NNS ._.
IFRS_NNS 7_CD Financial_NNP instruments_NNS :_: disclosures_NNS was_VBD issued_VBN in_IN August_NNP 2005_CD and_CC is_VBZ required_VBN to_TO be_VB implemented_VBN by_IN the_DT Group_NNP from_IN 1st_CD January_NNP 2007_CD ._.
This_DT new_JJ standard_JJ incorporates_VBZ the_DT disclosure_NN requirements_NNS of_IN IAS_NNP 32_CD ,_, which_WDT it_PRP supersedes_VBZ ,_, and_CC adds_VBZ further_JJ quantitative_JJ and_CC qualitative_JJ disclosures_NNS in_IN relation_NN to_TO financial_JJ instruments_NNS ._.
IFRIC_NNP 4_CD Determining_VBG whether_IN an_DT arrangement_NN contains_VBZ a_DT lease_NN was_VBD issued_VBN in_IN December_NNP 2004_CD and_CC is_VBZ required_VBN to_TO be_VB implemented_VBN by_IN the_DT Group_NNP from_IN 1_CD January_NNP 2006_CD ._.
The_DT interpretation_NN requires_VBZ arrangements_NNS which_WDT may_MD have_VB the_DT nature_NN ,_, but_CC not_RB the_DT legal_JJ form_NN ,_, of_IN a_DT lease_NN to_TO be_VB accounted_VBN for_IN in_IN accordance_NN with_IN IAS_NNP 17_CD Leases_NNS ._.
This_DT interpretation_NN is_VBZ not_RB expected_VBN to_TO have_VB a_DT material_NN impact_NN on_IN the_DT Group_NNP ._.
58_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 3_CD ._.
Business_NN and_CC geographical_JJ segments_NNS For_IN management_NN purposes_NNS ,_, the_DT Group_NNP is_VBZ organised_VBN into_IN three_CD operating_NN divisions_NNS Generics_NNP ,_, Branded_NNP and_CC Injectables_NNP ._.
These_DT divisions_NNS are_VBP the_DT basis_NN on_IN which_WDT the_DT Group_NNP reports_VBZ its_PRP$ primary_JJ segment_NN information_NN ._.
Segment_NN information_NN about_IN these_DT businesses_NNS is_VBZ presented_VBN below_IN ._.
Corporate_JJ Generics_NNPS Branded_NNP Injectable_NNP and_CC others_NNS Group_NNP 2005200520052005_CD 2005_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD Revenue_NN 115,208_CD 93,012_CD 49,303_CD 4,692_CD 262,215_CD Cost_NN of_IN sales_NNS 52,861_CD 39,297_CD 30,883_CD 3,383_CD 126,424_CD Gross_NNP profit_NN 62,347_CD 53,715_CD 18,420_CD 1,309_CD 135,791_CD Result_NN Segment_NN result_NN 38,765_CD 28,764_CD 8,486_CD 27_CD 75,988_CD Unallocated_JJ corporate_JJ expenses_NNS 8,229_CD Share_NN of_IN results_NNS of_IN associates_NNS 1,449_CD 1,449_CD Operating_NN profit_NN 69,208_CD Flotation_NN costs_NNS 1,426_CD Finance_NNP income_NN 1,562_CD Finance_NNP costs_NNS 5,211_CD Other_JJ income_NN 276_CD Profit_NN before_IN tax_NN 64,409_CD Tax_NNP 19,452_CD Minority_NNP interest_NN 1,090_CD Profit_NN for_IN the_DT year_NN attributable_JJ to_TO equity_NN shareholders_NNS 43,867_CD Corporate_JJ Generics_NNPS Branded_NNP Injectable_NNP and_CC others_NNS Group_NNP 2005200520052005_CD 2005_CD Other_JJ information_NN $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD Additions_NNS to_TO property_NN ,_, plant_NN and_CC equipment_NN assets_NNS cost_VBP 4,385_CD 12,364_CD 7,770_CD 1,680_CD 26,199_CD Acquisition_NNP of_IN subsidiarys_NNS property_NN ,_, plant_NN and_CC equipment_NN 9,857_CD 9,857_CD Additions_NNS to_TO intangible_JJ assets_NNS 282_CD 3,939_CD 4,221_CD Total_JJ property_NN ,_, plant_NN and_CC equipment_NN and_CC intangible_JJ assets_NNS net_JJ book_NN value_NN 25,600_CD 33,844_CD 30,408_CD 9,092_CD 98,944_CD Depreciation_NN and_CC amortisation_NN 4,879_CD 2,273_CD 2,133_CD 1,040_CD 10,325_CD Total_JJ investment_NN in_IN associated_VBN companies_NNS 7,552_CD 7,552_CD Balance_NN sheet_NN Assets_NNS Segment_NN assets_NNS 122,831_CD 140,631_CD 50,219_CD 89,113_CD 402,794_CD Liabilities_NNPS Segment_NNP liabilities_NNS 13,207_CD 62,937_CD 25,237_CD 13,931_CD 115,312_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP 59_CD 3_CD ._.
Business_NN and_CC geographical_JJ segments_NNS continued_VBD Corporate_NNP Group_NNP Generics_NNP Branded_NNP Injectable_NNP and_CC others_NNS Restated_VBN 2004200420042004_CD 2004_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD Revenue_NN 106,225_CD 74,013_CD 28,859_CD 3,280_CD 212,377_CD Cost_NN of_IN sales_NNS 48,773_CD 34,312_CD 19,140_CD 1,712_CD 103,937_CD Gross_NNP profit_NN 57,452_CD 39,701_CD 9,719_CD 1,568_CD 108,440_CD Result_NN Segment_NN result_NN 41,043_CD 22,441_CD 4,056_CD 986_CD 68,526_CD Unallocated_JJ corporate_JJ expenses_NNS 6,534_CD Share_NN of_IN results_NNS of_IN associates_NNS 732_CD 732_CD Operating_NN profit_NN 62,724_CD Flotation_NN costs_NNS 425_CD Finance_NNP income_NN 326_CD Finance_NNP costs_NNS 3,825_CD Other_JJ income_NN 224_CD Profit_NN before_IN tax_NN 59,024_CD Tax_NNP 20,835_CD Minority_NNP interest_NN 731_CD Profit_NN for_IN the_DT year_NN attributable_JJ to_TO equity_NN shareholders_NNS 37,458_CD Corporate_JJ Generics_NNPS Branded_NNP Injectable_NNP and_CC others_NNS Group_NNP 2004200420042004_CD 2004_CD Other_JJ information_NN $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD Additions_NNS to_TO property_NN ,_, plant_NN and_CC equipment_NN assets_NNS cost_VBP 6,139_CD 8,340_CD 2,133_CD 1,432_CD 18,044_CD Acquisition_NNP of_IN subsidiarys_NNS property_NN ,_, plant_NN and_CC equipment_NN 3,146_CD 3,146_CD Additions_NNS to_TO intangible_JJ assets_NNS 3,443_CD 778_CD 70_CD 4,291_CD Total_JJ property_NN ,_, plant_NN and_CC equipment_NN and_CC intangible_JJ assets_NNS net_JJ book_NN value_NN 25,271_CD 25,256_CD 18,373_CD 7,604_CD 76,504_CD Depreciation_NN and_CC amortisation_NN 2,036_CD 2,505_CD 1,412_CD 727_CD 6,680_CD Total_JJ investment_NN in_IN associated_VBN companies_NNS 6,103_CD 6,103_CD Balance_NN sheet_NN Assets_NNS Segment_NN assets_NNS 104,411_CD 93,493_CD 29,953_CD 18,624_CD 246,481_CD Liabilities_NNPS Segment_NNP liabilities_NNS 16,818_CD 45,783_CD 18,998_CD 19,707_CD 101,306_CD 60_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 3_CD ._.
Business_NN and_CC geographical_JJ segments_NNS continued_VBD The_DT following_JJ table_NN provides_VBZ an_DT analysis_NN of_IN the_DT Groups_NNS sales_NNS by_IN geographical_JJ market_NN ,_, irrespective_RB of_IN the_DT origin_NN of_IN the_DT goods_NNS services_NNS :_: Sales_NNS revenue_NN by_IN geographical_JJ market_NN 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD United_NNP States_NNPS 130,454_CD 113,101_CD Europe_NNP 20,445_CD 12,490_CD Middle_NNP East_NNP and_CC North_NNP Africa_NNP 111,283_CD 85,826_CD Rest_VBP of_IN the_DT world_NN 33960262_CD ,215_CD 212,377_CD The_DT following_NN is_VBZ an_DT analysis_NN of_IN the_DT additions_NNS to_TO property_NN ,_, plant_NN and_CC equipment_NN and_CC intangible_JJ assets_NNS ,_, an_DT analysis_NN of_IN total_JJ property_NN ,_, plant_NN and_CC equipment_NN and_CC intangible_JJ assets_NNS and_CC an_DT analysis_NN of_IN total_JJ assets_NNS by_IN the_DT geographical_JJ area_NN in_IN which_WDT the_DT assets_NNS are_VBP located_VBN :_: Additions_NNS to_TO property_NN ,_, plant_NN and_CC Total_JJ property_NN ,_, plant_NN and_CC equipment_NN and_CC intangibles_NNS equipment_NN and_CC intangibles_VBZ Total_JJ assets_NNS 2005200420052004_CD 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD United_NNP States_NNPS 4,385_CD 9,582_CD 25,600_CD 25,271_CD 122,832_CD 104,411_CD Europe_NNP 21,573_CD 2,912_CD 31,431_CD 18,373_CD 115,587_CD 30,377_CD Middle_NNP East_NNP and_CC North_NNP Africa_NNP 14,319_CD 12,987_CD 41,913_CD 32,860_CD 164,375_CD 111,693_CD 40,277_CD 25,481_CD 98,944_CD 76,504_CD 402,794_CD 246,481_CD Additions_NNS include_VBP property_NN ,_, plant_NN and_CC equipment_NN and_CC intangibles_NNS acquired_VBN with_IN and_CC arising_VBG on_IN the_DT acquisition_NN of_IN subsidiary_NN undertakings_NNS ._.
Profit_NN for_IN the_DT year_NN Profit_NN for_IN the_DT year_NN has_VBZ been_VBN arrived_VBN at_IN after_IN charging_VBG crediting_VBG :_: For_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Net_JJ foreign_JJ exchange_NN gains_NNS 217_CD 282_CD Research_NNP and_CC development_NN costs_NNS 16,507_CD 9,672_CD Loss_NN on_IN sale_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 440_CD 390_CD Depreciation_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 8,909_CD 6,680_CD Amortisation_NNP and_CC impairment_NN of_IN intangibles_NNS 1,416_CD Cost_NN of_IN inventories_NNS recognized_VBN as_IN expense_NN 83,648_CD 67,237_CD Write-down_NN of_IN inventories_NNS 855_CD 921_CD Staff_NN costs_NNS see_VBP Note_NN 5_CD 51,889_CD 36,894_CD Auditors_NNS remuneration_NN for_IN audit_NN services_NNS see_VBP below_IN 1,059_CD 439_CD A_DT more_JJR detailed_JJ analysis_NN of_IN auditors_NNS remuneration_NN on_IN a_DT worldwide_JJ basis_NN is_VBZ provided_VBN below_RB ._.
2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Audit_NNP fees_NNS 644_CD 409_CD Fees_NNS in_IN connection_NN with_IN the_DT float_NN 212_CD Other_JJ services_NNS 203_CD 30_CD 1,059_CD 439_CD In_IN addition_NN ,_, $_$ 1,995,000_CD of_IN fees_NNS in_IN relation_NN to_TO the_DT float_NN has_VBZ been_VBN set_VBN off_RP against_IN the_DT share_NN premium_NN account_NN ._.
Profit_NN for_IN the_DT year_NN continued_VBD A_DT description_NN of_IN the_DT work_NN of_IN the_DT Audit_NNP Committee_NNP is_VBZ set_VBN out_RP in_IN the_DT Audit_NNP Committee_NNP report_NN on_IN pages_NNS 35_CD and_CC 36_CD and_CC includes_VBZ an_DT explanation_NN of_IN how_WRB auditor_NN objectivity_NN and_CC independence_NN is_VBZ safeguarded_VBN when_WRB non-audit_JJ services_NNS are_VBP provided_VBN by_IN the_DT auditors_NNS ._.
Included_VBN in_IN the_DT amount_NN for_IN audit_NN services_NNS shown_VBN on_IN the_DT previous_JJ page_NN are_VBP the_DT audit_NN fees_NNS of_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP company_NN only_RB of_IN $_$ 50,000_CD ._.
Staff_NN costs_NNS The_DT average_JJ monthly_JJ number_NN of_IN employees_NNS including_VBG Executive_NNP Directors_NNS was_VBD :_: 2005_CD 2004_CD Number_NNP Number_NNP Production_NNP 1,052_CD 818_CD Selling_VBG and_CC marketing_VBG 363_CD 292_CD Research_NNP and_CC development_NN 160_CD 122_CD General_NNP and_CC administrative_JJ 252_CD 195_CD 1,827_CD 1,427_CD 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Their_PRP$ aggregate_JJ remuneration_NN comprised_VBN :_: Wages_NNS and_CC salaries_NNS 41,055_CD 29,662_CD Social_NNP security_NN costs_NNS 4,039_CD 2,702_CD Post_NNP employment_NN benefits_NNS 685_CD 615_CD End_NN of_IN service_NN indemnity_NN 843_CD 615_CD Other_JJ 5,267_CD 3,300_CD 51,889_CD 36,894_CD Other_JJ staff_NN costs_NNS mainly_RB consist_VBP of_IN health_NN insurance_NN ,_, training_NN ,_, housing_NN and_CC living_VBG allowances_NNS ._.
Other_JJ operating_NN expenses_NNS The_DT other_JJ operating_NN expenses_NNS consist_VBP mainly_RB of_IN damaged_VBN and_CC slow_JJ moving_VBG items_NNS and_CC the_DT cost_NN of_IN setting_VBG up_RP the_DT new_JJ manufacturing_NN facilities_NNS in_IN Algeria_NNP that_WDT commenced_VBD operations_NNS early_RB in_IN 2006_CD ._.
Other_JJ operating_NN income_NN The_DT other_JJ operating_NN income_NN consists_VBZ mainly_RB of_IN management_NN fees_NNS from_IN Al-Jazeera_NNP Pharmaceuticals_NNP Industries_NNP Co._NNP ._.
KSA_NNP and_CC foreign_JJ exchange_NN gains_NNS ._.
Flotation_NN costs_NNS The_DT total_JJ costs_NNS of_IN flotation_NN were_VBD $_$ 12,661,000_CD ,_, of_IN which_WDT costs_VBZ incurred_VBN in_IN issuing_VBG shares_NNS amounting_VBG to_TO $_$ 10,810,000_CD have_VBP been_VBN charged_VBN against_IN the_DT share_NN premium_NN account_NN ._.
The_DT remaining_VBG amount_NN of_IN $_$ 1,851,000_CD incurred_VBN as_IN a_DT result_NN of_IN the_DT listing_NN exercise_NN ,_, but_CC which_WDT was_VBD not_RB eligible_JJ to_TO be_VB set_VBN against_IN the_DT share_NN premium_NN ,_, has_VBZ been_VBN reflected_VBN in_IN flotation_NN costs_NNS within_IN the_DT income_NN statement_NN ,_, of_IN which_WDT $_$ 1,426,000_CD and_CC $_$ 425,000_CD was_VBD recognized_VBN in_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2005_CD and_CC 2004_CD ,_, respectively_RB ._.
Finance_NNP income_NN For_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Interest_NN income_NN 1,562_CD 313_CD Net_JJ foreign_JJ exchange_NN 13_CD 1,562_CD 326_CD 62_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 10_CD ._.
Finance_NNP costs_VBZ For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Interest_NN on_IN bank_NN overdrafts_NNS and_CC loans_NNS 3,437_CD 2,498_CD Interest_NN on_IN obligations_NNS under_IN finance_NN leases_NNS 227_CD 436_CD Other_JJ bank_NN charges_NNS 1,547_CD 891_CD 5,211_CD 3,825_CD 11_CD ._.
Tax_NN For_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Current_JJ tax_NN :_: UK_NNP current_JJ tax_NN 110_CD Foreign_NNP tax_NN 19,596_CD 20,896_CD Deferred_JJ tax_NN Note_NN 17_CD 254_CD 61_CD 19,452_CD 20,835_CD UK_NNP corporation_NN tax_NN is_VBZ calculated_VBN at_IN 30_CD %_NN of_IN the_DT estimated_VBN assessable_JJ profit_NN for_IN the_DT year_NN ._.
At_IN 31_CD December_NNP 2004_CD the_DT Group_NNP was_VBD headed_VBN by_IN Hikma_NNP Pharma_NNP Limited_NNP ,_, a_DT company_NN incorporated_VBN in_IN Jersey_NNP where_WRB the_DT tax_NN rate_NN is_VBZ zero_CD ._.
The_DT charge_NN for_IN the_DT year_NN can_MD be_VB reconciled_VBN to_TO the_DT profit_NN per_IN the_DT income_NN statement_NN as_IN follows_VBZ :_: 2005_CD $_$ 000s_CD Profit_NN before_IN tax_NN 64,409_CD Tax_NNP at_IN the_DT UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN 19,323_CD Tax_NNP effect_NN of_IN share_NN of_IN results_NNS of_IN associates_NNS 435_CD Tax_NNP effect_NN of_IN expenses_NNS that_WDT are_VBP not_RB deductible_JJ in_IN determining_VBG taxable_JJ profit_NN 7_CD Tax_NNP effect_NN of_IN exempted_VBN revenues_NNS 3,023_CD Tax_NNP effect_NN of_IN losses_NNS for_IN which_WDT no_DT deferred_JJ tax_NN asset_NN is_VBZ recognized_VBN 1,520_CD Effect_NN of_IN different_JJ tax_NN rates_NNS of_IN subsidiaries_NNS operating_VBG in_IN other_JJ jurisdictions_NNS 2,427_CD Other_JJ adjustments_NNS 367_CD Tax_NNP expense_NN for_IN the_DT year_NN 19,452_CD No_DT reconciliation_NN is_VBZ provided_VBN for_IN 2004_CD as_IN the_DT company_NN was_VBD incorporated_VBN in_IN Jersey_NNP where_WRB the_DT tax_NN rate_NN is_VBZ zero_CD ._.
Dividends_NNS 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Amounts_NNS recognized_VBN as_IN distributions_NNS to_TO equity_NN holders_NNS in_IN the_DT period_NN :_: Final_JJ dividend_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD of_IN 5.0_CD cents_NNS per_IN share_NN 2003_CD :_: 2.6_CD cents_NNS per_IN share_NN 7,120_CD 3,766_CD Pre-float_JJ interim_JJ dividend_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD of_IN 7.5_CD cents_NNS per_IN share_NN 10,680_CD 17,800_CD 3,766_CD Proposed_VBN final_JJ dividend_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD of_IN 0.89_CD cents_NNS per_IN share_NN 2004_CD :_: 5.0_CD cents_NNS per_IN share_NN 1,500_CD 7,120_CD The_DT final_JJ dividend_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD and_CC the_DT pre-float_JJ interim_JJ dividend_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD were_VBD paid_VBN by_IN Hikma_NNP Pharma_NNP Limited_NNP which_WDT is_VBZ incorporated_VBN in_IN Jersey_NNP ._.
Earnings_NNS per_IN share_NN The_DT calculation_NN of_IN the_DT basic_JJ and_CC diluted_JJ earnings_NNS per_IN share_NN is_VBZ based_VBN on_IN the_DT following_VBG data_NNS :_: 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Earnings_NNS Earnings_NNS for_IN the_DT purposes_NNS of_IN basic_JJ and_CC diluted_JJ earnings_NNS per_IN share_NN being_VBG net_JJ profit_NN attributable_JJ to_TO equity_NN holders_NNS of_IN the_DT parent_NN 43,867_CD 37,458_CD Number_NNP Number_NNP Number_NNP of_IN shares_NNS Weighted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP for_IN the_DT purposes_NNS of_IN basic_JJ earnings_NNS per_IN share_NN 000_CD 146,454_CD 142,400_CD Effect_NN of_IN dilutive_JJ potential_JJ Ordinary_NNP Shares_NNP :_: Share_NN options_NNS 000_CD 8,402_CD 7,843_CD Weighted_VBN average_JJ number_NN of_IN ordinary_JJ shares_NNS for_IN the_DT purposes_NNS of_IN diluted_JJ earnings_NNS per_IN share_NN 000_CD 154,856_CD 150,243_CD Basic_JJ Cents_NNS 30.0_CD 26.3_CD Diluted_NNP Cents_NNP 28.3_CD 24.8_CD 14_CD ._.
Goodwill_NN of_IN $_$ 70,000_CD arose_VBD on_IN the_DT acquisition_NN of_IN the_DT Groups_NNS shares_NNS of_IN IPRC_NNP and_CC SPRC_NNP in_IN 2004_CD ._.
The_DT additions_NNS to_TO goodwill_NN in_IN 2005_CD represent_VBP the_DT acquisition_NN of_IN the_DT Italian_JJ subsidiary_NN IBPP_NNP see_VB Note_VB 36_CD ._.
In_IN accordance_NN with_IN International_NNP Accounting_NNP Standard_NNP 38_CD Intangible_NNP Assets_NNPS IAS_NNP 38_CD the_DT Group_NNP has_VBZ tested_VBN its_PRP$ goodwill_NN for_IN impairment_NN and_CC assessed_VBN that_IN the_DT fair_JJ value_NN exceeds_VBZ its_PRP$ book_NN value_NN ,_, therefore_RB no_DT impairment_NN has_VBZ been_VBN taken_VBN to_TO the_DT income_NN statement_NN ._.
Marketing_NNP rights_NNS were_VBD acquired_VBN in_IN 2005_CD and_CC 2004_CD and_CC are_VBP being_VBG amortised_VBN over_IN a_DT period_NN of_IN three_CD to_TO five_CD years_NNS from_IN the_DT time_NN they_PRP generate_VBP sales_NNS ._.
Product_NN files_NNS were_VBD acquired_VBN at_IN 14_CD March_NNP 2005_CD on_IN the_DT acquisition_NN of_IN the_DT Italian_JJ subsidiary_NN IBPP_NNP ._.
The_DT product_NN files_NNS have_VBP an_DT indefinite_JJ useful_JJ life_NN and_CC are_VBP being_VBG reviewed_VBN for_IN impairment_NN test_NN at_IN least_JJS annually_RB ._.
Software_NNP represents_VBZ the_DT new_JJ Enterprise_NN Resource_NNP Planning_NNP solution_NN ERP_NNP that_IN the_DT Company_NN implemented_VBN in_IN January_NNP 2005_CD ._.
An_DT impairment_NN charge_NN of_IN $_$ 250,000_CD has_VBZ been_VBN recognized_VBN during_IN 2005_CD in_IN relation_NN to_TO software_NN which_WDT no_RB longer_RB has_VBZ any_DT beneficial_JJ interest_NN to_TO the_DT Group_NNP ._.
64_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 15_CD ._.
As_IN at_IN 31_CD December_NNP 2005_CD the_DT Group_NNP had_VBD pledged_VBN property_NN ,_, plant_NN and_CC equipment_NN ,_, having_VBG a_DT carrying_VBG value_NN of_IN $_$ 31,538,000_CD of_IN which_WDT an_DT amount_NN of_IN $_$ 6,743,000_CD was_VBD pledged_VBN to_TO International_NNP Finance_NNP Corporation_NNP ._.
In_IN 1994_CD ,_, the_DT Portuguese_NNP Government_NNP granted_VBD Hikma_NNP Farmacutica_NNP an_DT amount_NN of_IN Euro_NNP 1,600,000_CD to_TO build_VB the_DT Companys_NNPS factory_NN in_IN accordance_NN with_IN the_DT SINPEDIP_NNP program_NN ._.
The_DT grant_NN amount_NN is_VBZ being_VBG released_VBN to_TO the_DT income_NN statement_NN over_IN the_DT period_NN necessary_JJ to_TO match_VB it_PRP with_IN the_DT assets_NNS life_NN ._.
The_DT carrying_VBG value_NN of_IN the_DT grant_NN as_IN of_IN 31_CD December_NNP 2005_CD was_VBD $_$ 416,000_CD 31_CD December_NNP 2004_CD :_: $_$ 591,000_CD ._.
The_DT Directors_NNS were_VBD not_RB aware_JJ of_IN any_DT significant_JJ contractual_JJ commitments_NNS other_JJ than_IN those_DT disclosed_VBN in_IN the_DT accounts_NNS as_IN of_IN 31_CD December_NNP 2005_CD 2004_CD :_: $_$ 1,600,000_CD ._.
The_DT amount_NN of_IN borrowing_NN costs_NNS that_WDT was_VBD capitalized_VBN on_IN the_DT projects_NNS under_IN construction_NN is_VBZ $_$ 300,000_CD 2004_CD :_: nil_NN ._.
Interest_NN in_IN associate_JJ Summarised_JJ financial_JJ information_NN in_IN respect_NN of_IN the_DT Groups_NNS 47.5_CD %_NN interest_NN in_IN the_DT Ordinary_NNP Shares_NNP of_IN Al-Jazeera_NNP Pharmaceutical_NNP Industries_NNPS Co._NNP incorporated_VBN in_IN KSA_NNP is_VBZ set_VBN out_RP below_IN :_: For_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Total_JJ assets_NNS 47,773_CD 40,690_CD Total_JJ liabilities_NNS 31,874_CD 27,842_CD Net_JJ assets_NNS 15,899_CD 12,848_CD Interest_NN in_IN associate_JJ 7,552_CD 6,103_CD Revenues_NNS 30,371_CD 23,347_CD Profit_NN 3,050_CD 1,541_CD Share_NN of_IN result_NN of_IN associate_JJ 1,449_CD 732_CD Profit_NN is_VBZ stated_VBN after_IN management_NN fees_NNS of_IN $_$ 1,061,000_CD 2004_CD :_: $_$ 333,000_CD paid_VBN to_TO the_DT Group_NNP ._.
Deferred_JJ tax_NN The_DT following_VBG are_VBP the_DT major_JJ deferred_JJ tax_NN liabilities_NNS and_CC assets_NNS recognized_VBN by_IN the_DT Group_NNP and_CC movements_NNS thereon_NN during_IN the_DT current_JJ and_CC prior_JJ reporting_NN period_NN ._.
AmortisSoftware_NNP Deferred_NNP Reserves_NNPS Interest_NNP able_JJ Fixed_NNP Stock_NNP developTax_NNP losses_NNS R&D_NNP costs_NNS and_CC others_NNS rate_NN swaps_NNS assets_NNS assets_NNS options_NNS ment_NN Total_JJ $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD At_IN 1_CD January_NNP 2004129482_CD 91_CD 50_CD 1,284_CD 532_CD Charge_NNP to_TO income_NN 28_CD 1,620_CD 91_CD 6_CD 300_CD 1,312_CD 61_CD Exchange_NNP differences_NNS 14_CD 6_CD 20_CD At_IN 1_CD January_NNP 2005_CD 171_CD 2,102_CD 44_CD 1,578_CD 1,312_CD 573_CD Charge_NNP credit_NN to_TO income_NN 128_CD 213_CD 1917287214_CD 410_CD 254_CD Charge_NNP credit_NN to_TO equity_NN 960_CD 960_CD Acquisition_NNP of_IN subsidiary_NN 357651294_CD Exchange_NNP differences_NNS 43_CD 29_CD 69_CD 3_CD As_IN 31_CD December_NNP 2005314270_CD 1,889_CD 19_CD 27_CD 2,447_CD 1,174_CD 902_CD 344_CD Certain_NNP deferred_VBN tax_NN assets_NNS and_CC liabilities_NNS have_VBP been_VBN offset_VBN ._.
The_DT following_NN is_VBZ the_DT analysis_NN of_IN the_DT deferred_JJ tax_NN balances_NNS after_IN offset_VBN for_IN financial_JJ reporting_NN purposes_NNS :_: 2005_CD 2004_CD $_$ $_$ Deferred_JJ tax_NN liabilities_NNS 1,162_CD 744_CD Deferred_JJ tax_NN assets_NNS 1,506_CD 171344573_CD A_DT deferred_JJ tax_NN asset_NN on_IN unused_JJ tax_NN losses_NNS totalling_VBG $_$ 226,000_CD has_VBZ not_RB been_VBN recognized_VBN in_IN the_DT year_NN due_JJ to_TO the_DT unpredictability_NN of_IN future_JJ profit_NN streams_NNS ._.
These_DT losses_NNS may_MD be_VB carried_VBN forward_RB indefinitely_RB ._.
In_IN addition_NN there_EX is_VBZ a_DT deferred_JJ tax_NN asset_NN of_IN approximately_RB $_$ 310,000_CD on_IN other_JJ deductible_JJ temporary_JJ differences_NNS which_WDT has_VBZ not_RB been_VBN recognized_VBN due_JJ to_TO uncertainty_NN regarding_VBG the_DT tax_NN treatment_NN of_IN the_DT profits_NNS against_IN which_WDT these_DT differences_NNS will_MD reverse_VB ._.
66_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 18_CD ._.
Available_JJ for_IN sale_NN investments_NNS The_DT investment_NN in_IN available_JJ for_IN sale_NN securities_NNS represents_VBZ investments_NNS in_IN listed_VBN equity_NN securities_NNS and_CC unlisted_JJ securities_NNS that_WDT are_VBP recorded_VBN at_IN the_DT fair_JJ value_NN based_VBN on_IN either_DT quoted_VBN market_NN price_NN for_IN listed_VBN companies_NNS or_CC using_VBG other_JJ valuation_NN methods_NNS for_IN unlisted_JJ companies_NNS ._.
As_IN at_IN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Listed_VBN companies_NNS 1,185_CD 171_CD Non-listed_JJ companies_NNS 254_CD 254_CD 1,439_CD 425_CD Included_VBN in_IN this_DT amount_NN is_VBZ an_DT investment_NN in_IN a_DT non-listed_JJ US_NNP company_NN MENA_NNP Innovative_JJ Technologies_NNPS Inc._NNP of_IN $_$ 141,000_CD 2004_CD :_: $_$ 141,000_CD that_WDT represents_VBZ 32.5_CD %_NN of_IN its_PRP$ common_JJ share_NN for_IN which_WDT the_DT management_NN does_VBZ not_RB exert_VB significant_JJ influence_NN as_IN it_PRP has_VBZ no_DT representation_NN on_IN the_DT Board_NNP of_IN Directors_NNS of_IN the_DT company_NN ._.
Financial_NNP and_CC other_JJ non-current_JJ assets_NNS As_IN at_IN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Investments_NNP recorded_VBN at_IN cost_NN 488_CD 488_CD Amounts_NNS due_JJ from_IN investments_NNS recorded_VBN at_IN cost_NN 511_CD 554_CD Other_JJ financial_JJ assets_NNS 277_CD 147_CD 1,276_CD 1,189_CD Investments_NNP at_IN cost_NN represent_VBP the_DT Groups_NNS share_NN of_IN 32_CD %_NN 2004_CD :_: 32_CD %_NN and_CC 49_CD %_NN 2004_CD :_: 49_CD %_NN in_IN Societe_NNP Hikma_NNP Pharma_NNP Tunisia_NNP and_CC Societe_NNP DIndustries_NNP Pharmaceutiques_NNP Ibn_NNP Al_NNP Baytar_NNP S._NNP A._NNP Tunisia_NNP ,_, over_IN which_WDT the_DT Company_NN does_VBZ not_RB exert_VB significant_JJ influence_NN due_JJ to_TO a_DT number_NN of_IN factors_NNS including_VBG its_PRP$ limited_JJ representation_NN on_IN the_DT Board_NNP of_IN Directors_NNS of_IN these_DT companies_NNS ._.
On_IN 17_CD March_NNP 2005_CD the_DT Group_NNP signed_VBD an_DT agreement_NN with_IN Societe_NNP DIndustries_NNP Pharmaceutiques_NNP Ibn_NNP Al_NNP Baytar_NNP S._NNP A._NNP Tunisia_NNP ,_, to_TO sell_VB the_DT Groups_NNS share_NN in_IN Societe_NNP Hikma_NNP Ibn_NNP Al_NNP Baytar_NNP Limited_NNP Tunisia_NNP for_IN a_DT total_JJ value_NN equivalent_NN to_TO Tunisian_NNP Dinar_NNP 400,000_CD $_$ 333,000_CD to_TO be_VB paid_VBN in_IN four_CD instalments_NNS within_IN nine_CD months_NNS from_IN 17_CD March_NNP 2005_CD ._.
In_IN the_DT year_NN to_TO 31_CD December_NNP 2005_CD the_DT Group_NNP has_VBZ received_VBN three_CD instalments_NNS totalling_VBG $_$ 241,000_CD ,_, which_WDT have_VBP been_VBN recognized_VBN as_IN other_JJ income_NN in_IN the_DT income_NN statement_NN as_IN the_DT net_JJ book_NN value_NN of_IN the_DT investment_NN amounted_VBD to_TO one_CD US_NNP Dollar_NNP ._.
Amounts_NNS due_RB from_IN investments_NNS recorded_VBN at_IN cost_NN include_VBP $_$ 162,000_CD 2004_CD :_: $_$ 162,000_CD ,_, and_CC $_$ 459,000_CD 2004_CD :_: $_$ 554,000_CD due_JJ from_IN Societe_NNP Hikma_NNP Pharma_NNP Tunisia_NNP and_CC Societe_NNP DIndustries_NNP Pharmaceutiques_NNP Ibn_NNP Al_NNP Baytar_NNP S._NNP A._NNP Tunisia_NNP ,_, respectively_RB ._.
While_IN the_DT remaining_VBG amount_NN of_IN $_$ 188,000_CD 2004_CD :_: $_$ 514,000_CD represents_VBZ the_DT amount_NN due_JJ form_NN Societe_NNP Hikma_NNP Ibn_NNP Al_NNP Baytar_NNP Limited_NNP Tunisia_NNP ,_, which_WDT was_VBD sold_VBN to_TO Societe_NNP DIndustries_NNP Pharmaceutiques_NNP Ibn_NNP Al_NNP Baytar_NNP S._NNP A._NNP Tunisia_NNP as_IN mentioned_VBN above_IN ._.
The_DT amounts_NNS due_RB from_IN Societe_NNP Hikma_NNP Pharma_NNP Tunisia_NNP and_CC Societe_NNP Hikma_NNP Ibn_NNP Al_NNP Baytar_NNP Limited_NNP Tunisia_NNP are_VBP stated_VBN after_IN provision_NN for_IN doubtful_JJ debts_NNS of_IN $_$ 298,000_CD 2004_CD :_: $_$ 676,000_CD ._.
Inventories_NNS As_IN at_IN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Finished_VBN goods_NNS 14,868_CD 14,777_CD Work-in-progress_JJ 13,150_CD 7,890_CD Raw_NNP and_CC packing_VBG materials_NNS 24,247_CD 17,791_CD Goods_NNP in_IN transit_NN 5,752_CD 3,907_CD 58,017_CD 44,365_CD Goods_NNP in_IN transit_NN include_VBP inventory_NN held_VBN at_IN third_JJ parties_NNS whilst_VBP in_IN transit_NN between_IN Group_NNP companies_NNS ._.
Trade_NNP and_CC other_JJ receivables_NN As_IN at_IN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Trade_NNP receivables_NN 77,441_CD 60,151_CD Other_JJ prepayments_NNS 5,389_CD 1,762_CD Interest_NN receivable_NN 217_CD 30_CD Employee_NN advances_NNS 68_CD 29_CD Value_NNP added_VBD tax_NN recoverable_JJ 3,889_CD 1,733_CD Other_JJ receivables_NN 462_CD 27_CD 87,466_CD 63,732_CD Trade_NNP receivables_NNS are_VBP stated_VBN net_NN of_IN provisions_NNS for_IN chargebacks_NNS in_IN the_DT US_NNP ,_, doubtful_JJ debts_NNS and_CC expired_VBD goods_NNS as_IN follows_VBZ :_: As_IN at_IN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Charge_NNP backs_NNS 15,828_CD 18,125_CD Doubtful_JJ debts_NNS 4,408_CD 3,432_CD Expired_VBN goods_NNS 1,693_CD 1,216_CD 21,929_CD 22,773_CD 22_CD ._.
Collateralised_NNP cash_NN Collateralised_NNP cash_NN represents_VBZ an_DT amount_NN equal_JJ to_TO 105_CD %_NN of_IN bank_NN facilities_NNS granted_VBN to_TO the_DT Groups_NNS Algerian_NNP operations_NNS ._.
Cash_NN and_CC cash_NN equivalents_NNS As_IN at_IN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Cash_NN on_IN hand_NN and_CC at_IN banks_NNS 33,405_CD 13,864_CD Time_NNP deposits_NNS 1,194_CD 2,562_CD Money_NN market_NN deposits_NNS 101,025_CD 24,980_CD Restricted_VBN cash_NN 335_CD 9_CD 135,959_CD 41,415_CD Cash_NN and_CC cash_NN equivalents_NNS include_VBP highly_RB liquid_JJ investments_NNS with_IN maturities_NNS of_IN three_CD months_NNS or_CC less_JJR ._.
Bank_NNP overdrafts_NNS and_CC loans_NNS As_IN at_IN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Overdrafts_NNPS 866_CD 13,283_CD Import_NN and_CC export_NN financing_NN 5,208_CD 13,013_CD Short-term_JJ loans_NNS 7,267_CD 103_CD Current_JJ portion_NN of_IN long-term_JJ loans_NNS Note_VBP 27_CD 7,805_CD 8,619_CD Fair_NNP value_NN of_IN derivative_JJ financial_JJ instruments_NNS 90_CD 21,146_CD 35,108_CD 68_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 24_CD ._.
Bank_NNP overdrafts_NNS and_CC loans_NNS continued_VBD 2005_CD 2004_CD %_NN %_NN The_DT weighted_JJ average_JJ interest_NN rates_NNS paid_VBN were_VBD as_IN follows_VBZ :_: Bank_NNP overdrafts_NNS 4.16_CD 3.30_CD Bank_NNP loans_NNS including_VBG the_DT non-current_JJ bank_NN loans_NNS 5.14_CD 4.89_CD Import_NN and_CC export_NN financing_NN represent_VBP short-term_JJ financing_NN for_IN the_DT ordinary_JJ trading_NN activities_NNS of_IN the_DT business_NN ._.
Trade_NNP and_CC other_JJ payables_NNS As_IN at_IN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Trade_NNP payables_NNS 26,738_CD 16,612_CD Accrued_VBN expenses_NNS 16,537_CD 10,332_CD Employees_NNS provident_JJ fund_NN 2,301_CD 1,563_CD VAT_NNP and_CC sales_NNS tax_NN payables_NNS 1,425_CD 854_CD Dividends_NNS payable_JJ 841_CD 93_CD Social_NNP security_NN withholdings_NNS 416_CD 118_CD Income_NNP tax_NN withholdings_NNS 378_CD 182_CD Other_JJ payables_NNS 213_CD 58_CD 48,849_CD 29,812_CD The_DT employees_NNS provident_JJ fund_NN liability_NN represents_VBZ outstanding_JJ contributions_NNS to_TO the_DT Hikma_NNP Pharmaceuticals_NNP Limited_NNP Jordan_NNP retirement_NN benefit_NN plan_NN on_IN which_WDT the_DT fund_NN receive_VB 5_CD %_NN interest_NN ._.
Other_JJ provisions_NNS Other_JJ provisions_NNS represent_VBP the_DT end_NN of_IN service_NN indemnity_NN provisions_NNS of_IN Hikma_NNP Pharmaceuticals_NNP Limited_NNP Jordan_NNP ,_, Istituto_NNP Biochimico_NNP Pavese_NNP Pharma_NNP S._NNP P._NNP A_NNP Italy_NNP ,_, and_CC Pharma_NNP Ixir_NNP Co._NNP ._.
Ltd_NNP Sudan_NNP ._.
This_DT provision_NN represents_VBZ a_DT one_CD month_NN salary_NN payable_JJ for_IN each_DT year_NN employed_VBN for_IN certain_JJ individuals_NNS in_IN accordance_NN with_IN the_DT agreements_NNS for_IN the_DT Group_NNP employees_NNS for_IN Hikma_NNP Pharmaceuticals_NNP Limited_NNP Jordan_NNP and_CC Pharma_NNP Ixir_NNP Co_NNP ,_, Ltd._NNP ._.
Regarding_VBG IBPP_NNP ,_, the_DT staff_NN leaving_VBG indemnity_NN is_VBZ not_RB funded_VBN ,_, and_CC all_DT calculations_NNS necessary_JJ to_TO determine_VB the_DT annual_JJ expense_NN are_VBP determined_VBN in_IN accordance_NN with_IN Italian_JJ law_NN ._.
The_DT annual_JJ accrual_NN for_IN staff_NN indemnity_NN is_VBZ calculated_VBN by_IN dividing_VBG the_DT employees_NNS remuneration_NN for_IN the_DT year_NN by_IN 13.5_CD and_CC it_PRP is_VBZ subject_JJ to_TO revaluation_NN on_IN a_DT yearly_JJ basis_NN ._.
Movements_NNS on_IN the_DT provision_NN of_IN end_NN of_IN service_NN indemnity_NN :_: 2005_CD $_$ 000s_CD 1_CD January_NNP 829_CD Addition_NNP 733_CD Utilisation_NNP 300_CD Translation_NN adjustments_NNS 29_CD 31_CD December_NNP 1,233_CD As_IN at_IN 31_CD December_NNP 2005_CD ,_, the_DT balance_NN of_IN IBPPs_NNS provision_NN for_IN end_NN of_IN service_NN indemnity_NN was_VBD $_$ 327,000_CD ._.
Long-term_JJ financial_JJ debts_NNS As_IN at_IN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Total_JJ debts_NNS 38,596_CD 32,910_CD Less_RBR :_: current_JJ portion_NN of_IN debts_NNS 7,805_CD 8,619_CD Long-term_JJ financial_JJ debts_NNS 30,791_CD 24,291_CD As_IN at_IN 31_CD December_NNP 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Breakdown_VBN by_IN maturity_NN :_: Under_IN one_CD year_NN 7,805_CD 8,619_CD In_IN the_DT second_JJ year_NN 8,737_CD 7,901_CD In_IN third_JJ year_NN 8,357_CD 5,683_CD In_IN the_DT fourth_JJ year_NN 7,532_CD 4,634_CD In_IN the_DT fifth_JJ year_NN 4,065_CD 3,302_CD Thereafter_RB 2,100_CD 2,771_CD 38,596_CD 32,910_CD Breakdown_NNP by_IN currency_NN :_: US_NNP Dollar_NNP 22,302_CD 19,846_CD Euro_NNP 6,184_CD 6,255_CD Jordanian_NNP Dinar_NNP 9,989_CD 6,446_CD Algerian_NNP Dinar_NNP 121_CD 363_CD Long-term_JJ financial_JJ debts_NNS 38,596_CD 32,910_CD At_IN 31_CD December_NNP 2005_CD ,_, import_NN and_CC export_NN financing_NN ,_, short-term_JJ loans_NNS and_CC the_DT current_JJ and_CC long-term_JJ portion_NN of_IN long-term_JJ loans_NNS total_VBP $_$ 51,071,000_CD 2004_CD :_: $_$ 46,026,000_CD ._.
At_IN 31_CD December_NNP 2005_CD ,_, loans_NNS and_CC import_NN and_CC export_NN financing_NN of_IN $_$ 36,344,000_CD 2004_CD :_: $_$ 22,985,000_CD ,_, were_VBD arranged_VBN at_IN fixed_JJ interest_NN rates_NNS ._.
The_DT other_JJ borrowings_NNS at_IN 31_CD December_NNP 2005_CD of_IN $_$ 14,727,000_CD 2004_CD :_: $_$ 23,041,000_CD are_VBP arranged_VBN at_IN floating_VBG rates_NNS ,_, thus_RB exposing_VBG the_DT Group_NNP to_TO cash_NN flow_NN interest_NN rate_NN risk_NN ._.
Loans_NNS amounting_VBG to_TO $_$ 9,993,000_CD 2004_CD :_: $_$ 13,475,000_CD are_VBP secured_VBN on_IN property_NN ,_, plant_NN and_CC equipment_NN ._.
Obligations_NNS under_IN finance_NN leases_NNS Present_JJ value_NN of_IN Minimum_NNP lease_NN payments_NNS minimum_JJ lease_NN payments_NNS 2005200420052004_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD Amounts_NNS payable_JJ under_IN finance_NN leases_NNS :_: Within_IN one_CD year_NN 838_CD 1,297_CD 797_CD 1,165_CD In_IN the_DT second_JJ to_TO fifth_JJ years_NNS inclusive_JJ 1,441_CD 2,595_CD 1,411_CD 2,448_CD 2,279_CD 3,892_CD 2,208_CD 3,613_CD Less_RBR :_: interest_NN lease_NN charges_NNS 71_CD 279_CD Present_JJ value_NN of_IN minimum_JJ lease_NN payments_NNS payable_JJ 2,208_CD 3,613_CD 2,208_CD 3,613_CD Its_PRP$ the_DT Groups_NNS policy_NN to_TO lease_VB certain_JJ of_IN its_PRP$ fixtures_NNS and_CC equipment_NN under_IN finance_NN leases_NNS ._.
The_DT average_JJ lease_NN term_NN is_VBZ two_CD years_NNS 2004_CD :_: two_CD years_NNS ._.
For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD ,_, the_DT average_JJ effective_JJ borrowings_NNS rate_NN was_VBD between_IN 5.4_CD %_NN and_CC 6_CD %_NN 2004_CD :_: between_IN 4.8_CD %_NN and_CC 5.95_CD %_NN ._.
All_DT leases_NNS are_VBP on_IN fixed_VBN repayment_NN basis_NN and_CC no_DT arrangement_NN has_VBZ been_VBN entered_VBN into_IN for_IN contingent_JJ rental_JJ payment_NN ._.
70_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 29_CD ._.
Financial_JJ policies_NNS for_IN risk_NN management_NN and_CC their_PRP$ objectives_NNS Credit_NNP risk_NN The_DT Groups_NNS principal_JJ financial_JJ assets_NNS are_VBP bank_NN balances_NNS and_CC cash_NN ,_, trade_NN and_CC other_JJ receivables_NN ,_, finance_NN lease_NN receivables_NN and_CC investments_NNS ._.
The_DT Groups_NNS credit_NN risk_NN is_VBZ primarily_RB attributable_JJ to_TO its_PRP$ trade_NN and_CC finance_NN lease_NN receivables_NN ._.
The_DT amounts_NNS presented_VBN in_IN the_DT balance_NN sheet_NN are_VBP net_NN of_IN allowances_NNS for_IN doubtful_JJ receivables_NN ._.
An_DT allowance_NN for_IN impairment_NN is_VBZ made_VBN where_WRB there_EX is_VBZ an_DT identified_VBN loss_NN event_NN which_WDT ,_, based_VBN on_IN previous_JJ experience_NN ,_, is_VBZ evidence_NN of_IN a_DT reduction_NN in_IN the_DT recoverability_NN of_IN the_DT cash_NN flows_VBZ ._.
The_DT credit_NN risk_NN on_IN liquid_JJ funds_NNS and_CC derivative_JJ financial_JJ instruments_NNS is_VBZ limited_VBN because_IN the_DT counterparties_NNS are_VBP banks_NNS with_IN high_JJ credit-ratings_NNS assigned_VBN by_IN international_JJ credit-rating_NN agencies_NNS ._.
The_DT Group_NNP has_VBZ no_DT significant_JJ concentration_NN of_IN credit_NN risk_NN ,_, with_IN exposure_NN spread_NN over_IN a_DT large_JJ number_NN of_IN counterparties_NNS and_CC customers_NNS ._.
Market_NN risk_NN The_DT Group_NNP is_VBZ exposed_VBN to_TO foreign_JJ exchange_NN and_CC interest_NN rates_NNS risk_NN ._.
Management_NNP actively_RB monitors_VBZ these_DT exposures_NNS to_TO manage_VB the_DT volatility_NN relating_VBG to_TO these_DT exposures_NNS by_IN entering_VBG into_IN a_DT variety_NN of_IN derivatives_NNS financial_JJ instruments_NNS ._.
The_DT Groups_NNS objective_NN is_VBZ to_TO reduce_VB ,_, where_WRB it_PRP is_VBZ deemed_VBN appropriate_JJ to_TO do_VB so_RB ,_, fluctuations_NNS in_IN earnings_NNS and_CC cash_NN flow_NN associated_VBN with_IN changes_NNS in_IN interest_NN rates_NNS and_CC foreign_JJ currency_NN rates_NNS ._.
It_PRP is_VBZ the_DT Group_NNP policy_NN and_CC practice_NN to_TO use_VB derivative_JJ financial_JJ instruments_NNS to_TO manage_VB exposures_NNS to_TO interest_NN rates_NNS and_CC foreign_JJ currency_NN fluctuations_NNS ._.
Foreign_JJ exchange_NN risk_NN The_DT Group_NNP uses_VBZ the_DT US_NNP Dollar_NNP as_IN its_PRP$ reporting_NN currency_NN and_CC is_VBZ therefore_RB exposed_VBN to_TO foreign_JJ exchange_NN movements_NNS primarily_RB in_IN European_JJ ,_, Algerian_NNP and_CC Japanese_JJ currencies_NNS ._.
Consequently_RB it_PRP enters_VBZ into_IN various_JJ contracts_NNS ,_, which_WDT change_VBP in_IN value_NN as_IN foreign_JJ exchange_NN rates_NNS change_VBP to_TO hedge_VB against_IN the_DT risk_NN of_IN movement_NN in_IN foreign_JJ denominated_VBN assets_NNS and_CC liabilities_NNS ._.
Interest_NN rate_NN risk_NN The_DT Group_NNP manages_VBZ its_PRP$ exposures_NNS to_TO interest_NN rate_NN risks_NNS by_IN changing_VBG the_DT proportion_NN of_IN fixed_JJ rate_NN debt_NN and_CC variable_JJ rate_NN debt_NN in_IN its_PRP$ total_JJ debt_NN portfolio_NN ._.
To_TO manage_VB this_DT mix_NN ,_, the_DT Group_NNP may_MD enter_VB into_IN interest_NN rates_NNS swap_VBP agreements_NNS ,_, in_IN which_WDT it_PRP exchanges_NNS the_DT periodic_JJ payments_NNS based_VBN on_IN notional_JJ amounts_NNS and_CC agreed_VBD upon_IN fixed_VBN and_CC variable_JJ interest_NN rates_NNS ._.
Using_VBG the_DT above-mentioned_JJ derivative_JJ financial_JJ instruments_NNS has_VBZ not_RB had_VBD a_DT material_NN impact_NN on_IN the_DT Groups_NNS financial_JJ position_NN at_IN 31_CD December_NNP 2005_CD or_CC the_DT Groups_NNS results_NNS of_IN operations_NNS for_IN the_DT year_NN then_RB ended_VBD ._.
Fair_NNP value_NN of_IN financial_JJ assets_NNS and_CC liabilities_NNS :_: The_DT fair_JJ value_NN of_IN financial_JJ assets_NNS and_CC liabilities_NNS are_VBP included_VBN at_IN the_DT amount_NN at_IN which_WDT the_DT instrument_NN could_MD be_VB exchanged_VBN in_IN a_DT current_JJ transaction_NN between_IN willing_JJ parties_NNS ,_, other_JJ than_IN in_IN a_DT forced_VBN or_CC liquidation_NN sale_NN ._.
The_DT following_VBG methods_NNS and_CC assumptions_NNS were_VBD used_VBN to_TO estimate_VB the_DT fair_JJ value_NN :_: Cash_NN and_CC cash_NN equivalents_NNS approximates_VBZ to_TO the_DT carrying_VBG amount_NN ._.
Short-term_JJ loans_NNS and_CC overdrafts_NNS approximates_VBZ to_TO the_DT carrying_VBG amount_NN because_IN of_IN the_DT short_JJ maturity_NN of_IN these_DT instruments_NNS ._.
Long-term_JJ loans_NNS approximates_VBZ to_TO the_DT carrying_VBG amount_NN in_IN the_DT case_NN of_IN floating_VBG rate_NN bank_NN loans_NNS and_CC other_JJ loans_NNS ._.
Forward_RB exchange_NN contracts_NNS based_VBN on_IN market_NN prices_NNS and_CC exchange_NN rates_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
Receivables_NNPS and_CC payables_NNS approximates_VBZ to_TO the_DT carrying_VBG amount_NN ._.
Provisions_NNS approximates_VBZ to_TO the_DT carrying_VBG amount_NN ._.
Lease_NNP obligations_NNS approximates_VBZ to_TO the_DT carrying_VBG value_NN ._.
The_DT fair_JJ value_NN of_IN the_DT Groups_NNS financial_JJ assets_NNS and_CC liabilities_NNS do_VBP not_RB materially_RB differ_VBP form_VB their_PRP$ fair_JJ value_NN ._.
Derivative_JJ financial_JJ instruments_NNS Currency_NNP derivatives_NNS The_DT Group_NNP utilises_VBZ currency_NN derivatives_NNS to_TO hedge_VB significant_JJ future_JJ transactions_NNS and_CC cash_NN flows_NNS ._.
The_DT Group_NNP is_VBZ a_DT party_NN to_TO a_DT variety_NN of_IN foreign_JJ currency_NN forward_RB contracts_NNS and_CC options_NNS in_IN the_DT management_NN of_IN its_PRP$ exchange_NN rate_NN exposures_NNS ._.
The_DT instruments_NNS purchased_VBN are_VBP primarily_RB denominated_VBN in_IN the_DT currencies_NNS of_IN the_DT Groups_NNS principal_JJ markets_NNS ._.
At_IN the_DT balance_NN sheet_NN date_NN ,_, total_JJ notional_JJ amount_NN of_IN outstanding_JJ forward_RB foreign_JJ exchange_NN contracts_NNS that_IN the_DT Group_NNP has_VBZ committed_VBN are_VBP as_RB below_IN :_: 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Foreign_JJ exchange_NN forward_RB contracts_NNS Euro_NNP 414_CD Foreign_JJ exchange_NN forward_RB contracts_NNS Yen_NNP 300_CD Foreign_JJ exchange_NN option_NN contracts_NNS Euro_NNP 1,020_CD These_DT arrangements_NNS are_VBP designed_VBN to_TO address_VB significant_JJ exchange_NN exposures_NNS ._.
At_IN 31_CD December_NNP 2005_CD and_CC 2004_CD ,_, the_DT fair_JJ value_NN of_IN the_DT Groups_NNS currency_NN derivatives_NNS is_VBZ estimated_VBN to_TO be_VB $_$ 709,648_CD and_CC $_$ 1,016,647_CD respectively_RB ._.
The_DT fair_JJ valuation_NN of_IN the_DT currency_NN derivatives_NNS that_WDT are_VBP designated_VBN and_CC effective_JJ as_IN cash_NN flow_NN hedge_NN resulted_VBD in_IN a_DT loss_NN of_IN $_$ 4,847_CD and_CC a_DT loss_NN of_IN $_$ 3,128_CD for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2005_CD and_CC 2004_CD respectively_RB that_DT has_VBZ been_VBN deferred_VBN in_IN equity_NN ._.
These_DT amounts_NNS are_VBP based_VBN on_IN market_NN values_NNS of_IN equivalent_JJ instruments_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
Interest_NN rate_NN swaps_NNS The_DT Group_NNP uses_VBZ interest_NN rate_NN swaps_NNS to_TO manage_VB its_PRP$ exposure_NN to_TO interest_NN rate_NN movements_NNS on_IN its_PRP$ bank_NN borrowings_NNS ._.
Contracts_NNS with_IN original_JJ nominal_JJ values_NNS of_IN $_$ 19.5_CD million_CD as_IN at_IN 31_CD December_NNP 2004_CD increased_VBD to_TO $_$ 28_CD million_CD as_IN at_IN 31_CD December_NNP 2005_CD have_VBP fixed_VBN interest_NN payments_NNS at_IN rates_NNS ranging_VBG from_IN 2.8_CD %_NN to_TO 5.4_CD %_NN for_IN periods_NNS up_IN until_IN 2012_CD and_CC have_VBP floating_VBG interest_NN receipts_NNS ranging_VBG from_IN LIBOR_NNP to_TO LIBOR_NNP plus_CC 1.5_CD %_NN ._.
The_DT fair_JJ value_NN of_IN swaps_NNS entered_VBN into_IN by_IN the_DT Group_NNP is_VBZ estimated_VBN at_IN a_DT favourable_JJ value_NN of_IN $_$ 208,310_CD and_CC a_DT favourable_JJ value_NN of_IN $_$ 121,892_CD as_IN at_IN 31_CD December_NNP 2005_CD and_CC 2004_CD respectively_RB ._.
These_DT amounts_NNS are_VBP based_VBN on_IN market_NN values_VBZ provided_VBN by_IN the_DT banks_NNS that_WDT originated_VBP the_DT swaps_NNS and_CC are_VBP based_VBN on_IN equivalent_JJ instruments_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
Some_DT of_IN these_DT interest_NN rate_NN swaps_NNS are_VBP designated_VBN as_IN effective_JJ cash_NN flow_NN hedges_NNS and_CC the_DT fair_JJ value_NN thereof_RB has_VBZ been_VBN deferred_VBN in_IN equity_NN totalling_VBG $_$ 126,333_CD and_CC $_$ 32,386_CD for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2005_CD and_CC 2004_CD respectively_RB ,_, and_CC the_DT remainder_NN are_VBP designated_VBN as_IN ineffective_JJ cash_NN flow_NN hedges_NNS of_IN which_WDT the_DT change_NN in_IN their_PRP$ fair_JJ value_NN has_VBZ been_VBN taken_VBN to_TO earnings_NNS ._.
A_DT gain_NN of_IN $_$ 171,483_CD and_CC $_$ 81,328_CD for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2005_CD and_CC 2004_CD respectively_RB have_VBP been_VBN recognized_VBN in_IN the_DT income_NN statement_NN ._.
Share_NN capital_NN 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Authorised_VBN :_: 500,000,000_CD Ordinary_NNP Shares_NNP of_IN 10p_CD each_DT 88,700_CD 88,700_CD 49,998_CD non-voting_JJ ,_, Redeemable_JJ Preference_NN Shares_NNS of_IN 1_CD each_DT 90_CD 90_CD Issued_VBN and_CC fully_RB paid_VBN included_VBN in_IN shareholders_NNS equity_NN 166,798,407_CD Ordinary_NNP Shares_NNP of_IN 10p_CD each_DT 29,457_CD 25,269_CD Issued_VBN and_CC fully_RB paid_VBN included_VBN in_IN liabilities_NNS 49,998_CD non-voting_JJ ,_, Redeemable_JJ Preference_NN Shares_NNS of_IN 1_CD each_DT 90_CD The_DT Company_NN was_VBD incorporated_VBN on_IN 8_CD September_NNP 2005_CD with_IN an_DT authorised_JJ share_NN capital_NN of_IN 50,000_CD divided_VBN into_IN two_CD Ordinary_NNP Shares_NNP of_IN 1_CD each_DT and_CC 49,998_CD non-voting_JJ ,_, Redeemable_JJ Preference_NN Shares_NNS of_IN 1_CD each_DT ._.
The_DT two_CD Ordinary_NNP Shares_NNP of_IN 1_CD each_DT were_VBD transferred_VBN on_IN 8_CD September_NNP 2005_CD as_IN subscriber_NN shares_NNS at_IN a_DT price_NN of_IN 1_CD each_DT to_TO the_DT two_CD Executive_NNP Directors_NNS ,_, and_CC on_IN 15_CD September_NNP 2005_CD all_PDT the_DT Preference_NNP Shares_NNP were_VBD allotted_VBN to_TO the_DT Executive_NNP Directors_NNS ._.
The_DT Company_NN redeemed_VBD the_DT Preference_NNP Shares_NNP at_IN par_NN on_IN 9_CD February_NNP 2006_CD ._.
At_IN 31_CD December_NNP 2005_CD the_DT Preference_NN Shares_NNS were_VBD recorded_VBN as_IN a_DT financial_JJ liability_NN within_IN other_JJ current_JJ liabilities_NNS ._.
On_IN 31_CD October_NNP 2005_CD ,_, the_DT two_CD Ordinary_NNP Shares_NNP of_IN 1_CD each_DT were_VBD subdivided_VBN into_IN 10_CD Ordinary_NNP Shares_NNP of_IN 10_CD pence_NN each_DT and_CC the_DT authorised_JJ Ordinary_NNP Share_NN capital_NN of_IN the_DT Company_NN was_VBD increased_VBN to_TO 50_CD million_CD by_IN the_DT creation_NN of_IN an_DT additional_JJ 499,999,980_CD Ordinary_NNP Shares_NNP of_IN 10_CD pence_NN each_DT ._.
72_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 31_CD ._.
Share_NN capital_NN continued_VBD On_IN 31_CD October_NNP 2005_CD ,_, the_DT Company_NN acquired_VBD the_DT entire_JJ issued_JJ share_NN capital_NN of_IN Hikma_NNP Pharma_NNP Limited_NNP pursuant_JJ to_TO a_DT share_NN exchange_NN offer_NN ,_, following_VBG which_WDT it_PRP became_VBD the_DT holding_VBG company_NN of_IN the_DT Group_NNP ._.
Under_IN the_DT terms_NNS of_IN the_DT share_NN exchange_NN ,_, shareholders_NNS in_IN Hikma_NNP Pharma_NNP Limited_NNP received_VBD four_CD Ordinary_NNP Shares_NNP in_IN the_DT Company_NN for_IN every_DT one_CD share_NN held_VBN in_IN Hikma_NNP Pharma_NNP Limited_NNP ._.
Total_JJ shares_NNS issued_VBN and_CC fully_RB paid_VBN were_VBD 142,400,020_CD Ordinary_NNP Shares_NNP of_IN 10_CD pence_NN each_DT ._.
On_IN 1_CD November_NNP 2005_CD ,_, and_CC as_IN a_DT result_NN of_IN a_DT placing_NN ,_, 24,137,931_CD Ordinary_NNP Shares_NNP of_IN 10_CD pence_NN each_DT were_VBD issued_VBN at_IN a_DT price_NN of_IN 290p_JJ per_IN Ordinary_NNP Share_NNP ._.
On_IN 30_CD November_NNP 2005_CD ,_, the_DT Company_NN allotted_VBD 260,456_CD Ordinary_NNP Shares_NNP at_IN a_DT price_NN of_IN 290_CD pence_NN per_IN Ordinary_NNP Share_NNP pursuant_JJ to_TO the_DT exercise_NN of_IN an_DT over-allotment_NN option_NN ._.
Share_NN premium_NN Share_NN premium_NN $_$ 000s_CD Balance_NN at_IN 1_CD January_NNP 2004_CD ,_, 31_CD December_NNP 2004_CD and_CC 1_CD January_NNP 2005_CD Premium_NNP arising_VBG on_IN issue_NN of_IN Equity_NNP Shares_NNP 120,725_CD Expenses_NNS of_IN issue_NN of_IN Equity_NNP Shares_NNP 10,810_CD Treasury_NNP Shares_NNP 159_CD Balance_NN at_IN 31_CD December_NNP 2005_CD 110,074_CD 33_CD ._.
Treasury_NNP shares_NNS 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Balance_NN at_IN 1_CD January_NNP 187_CD 193_CD Sale_NN of_IN Treasury_NNP Shares_NNP 346_CD 4,841_CD Purchase_NN of_IN Treasury_NNP Shares_NNP 4,835_CD Transfer_NNP to_TO share_VB premium_JJ 159_CD Balance_NN at_IN 31_CD December_NNP 187_CD The_DT number_NN of_IN shares_NNS held_VBN at_IN 31_CD December_NNP 2004_CD was_VBD 91,743_CD shares_NNS ._.
Reserves_NNS Cumulative_JJ Merger_NNP Retained_VBD translation_NN Total_JJ reserve_NN earnings_NNS reserve_NN reserve_NN $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD At_IN 1_CD January_NNP 2004_CD 33,920_CD 48,043_CD 190_CD 82,153_CD Cost_NN of_IN equity_NN settled_VBN employee_NN share_NN scheme_NN 145_CD 145_CD Dividends_NNS on_IN Ordinary_NNP Shares_NNP 3,766_CD 3,766_CD Profit_NN for_IN the_DT year_NN 37,458_CD 37,458_CD Cumulative_JJ effect_NN of_IN change_NN in_IN fair_JJ value_NN of_IN available_JJ for_IN sale_NN investments_NNS 92_CD 92_CD Cumulative_JJ effect_NN of_IN change_NN in_IN fair_JJ value_NN of_IN financial_JJ derivatives_NNS 168_CD 168_CD Currency_NNP translation_NN gain_NN 1,158_CD 1,158_CD At_IN 31_CD December_NNP 2004_CD 33,920_CD 82,140_CD 1,348_CD 117,408_CD Cost_NN of_IN equity_NN settled_VBN employee_NN share_NN scheme_NN 712_CD 712_CD Deferred_JJ tax_NN arising_VBG on_IN stock_NN options_NNS 960_CD 960_CD Dividends_NNS on_IN Ordinary_NNP Shares_NNP 17,800_CD 17,800_CD Profit_NN for_IN the_DT year_NN 43,867_CD 43,867_CD Cumulative_JJ effect_NN of_IN change_NN in_IN fair_JJ value_NN of_IN available_JJ for_IN sale_NN investments_NNS 980_CD 980_CD Cumulative_JJ effect_NN of_IN change_NN in_IN fair_JJ value_NN of_IN financial_JJ derivatives_NNS 164_CD 164_CD Currency_NNP translation_NN gain_NN 1,941_CD 1,941_CD At_IN 31_CD December_NNP 2005_CD 33,920_CD 111,023_CD 593_CD 144,350_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP 73_CD 35_CD ._.
Minority_NNP interest_NN 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD At_IN 1_CD January_NNP 2,685_CD 697_CD Minority_NNP interest_NN share_NN of_IN profit_NN 1,090_CD 731_CD Other_JJ movements_NNS including_VBG foreign_JJ exchange_NN 174_CD 1,257_CD At_IN 31_CD December_NNP 3,601_CD 2,685_CD 36_CD ._.
Acquisition_NNP of_IN subsidiary_NN On_IN 14_CD March_NNP 2005_CD ,_, the_DT Group_NNP acquired_VBD 100_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN Istituto_NNP Biochimico_NNP Pavese_NNP Pharma_NNP S._NNP P._NNP A_NNP IBPP_NNP located_VBN in_IN Italy_NNP for_IN cash_NN consideration_NN of_IN Euro_NNP 500,000_CD $_$ 673,100_CD and_CC deferred_VBN consideration_NN of_IN Euro_NNP 500,000_CD to_TO be_VB paid_VBN in_IN 2006_CD subject_JJ to_TO certain_JJ conditions_NNS ._.
The_DT IBPP_NNP business_NN concerns_VBZ the_DT antiseptic_JJ manufacturing_NN of_IN injectable_JJ products_NNS solutions_NNS and_CC lyophilized_VBN powders_NNS in_IN vials_NNS and_CC ampoules_NNS ._.
The_DT net_JJ assets_NNS acquired_VBN in_IN the_DT transaction_NN and_CC the_DT goodwill_NN arising_VBG are_VBP set_VBN out_RP below_IN :_: Fair_NNP value_NN Book_NN value_NN adjustment_NN Fair_NNP value_NN $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD Net_JJ assets_NNS acquired_VBD Product_NNP files_NNS 1,222_CD 1,359_CD 2,581_CD Property_NN ,_, plant_NN and_CC equipment_NN 5,464_CD 1,148_CD 6,612_CD Deferred_JJ taxes_NNS 357651294_CD Financial_JJ assets_NNS 1_CD 1_CD Inventory_NNP 346_CD 346_CD Other_JJ current_JJ assets_NNS 159_CD 159_CD Accounts_NNPS receivable_NN ,_, net_JJ 1,529_CD 106_CD 1,423_CD Cash_NN and_CC cash_NN equivalents_NNS 4_CD 4_CD Trade_NNP accounts_NNS payable_JJ 1,207_CD 1,207_CD Capital_NN lease_NN obligations_NNS 541_CD 541_CD Bank_NNP overdrafts_NNS and_CC loans_NNS 2,164_CD 2,164_CD Provision_NNP for_IN end_NN of_IN service_NN indemnity_NN 288_CD 288_CD Other_JJ current_JJ liabilities_NNS 1,797_CD 1,256_CD 3,053_CD Long-term_JJ financial_JJ debts_NNS 1,894_CD 1,894_CD Capital_NN lease_NN obligations_NNS 1,163_CD 1,163_CD 28494522_CD Goodwill_NNP 976_CD Total_JJ consideration_NN 1,498_CD Satisfied_VBN by_IN :_: Cash_NN 673_CD Deferred_JJ consideration_NN 673_CD Directly_RB attributable_JJ costs_NNS 152_CD 1,498_CD Net_JJ cash_NN outflow_NN arising_VBG on_IN acquisition_NN Cash_NN consideration_NN 673_CD Cash_NN and_CC cash_NN equivalents_NNS acquired_VBD 4_CD 669_CD Directly_RB attributable_JJ acquisition_NN costs_NNS include_VBP legal_JJ and_CC accounting_NN costs_NNS incurred_VBN in_IN the_DT preparation_NN of_IN the_DT acquisition_NN contracts_NNS and_CC in_IN performing_VBG due_JJ diligence_NN activities_NNS ._.
The_DT Group_NNP placed_VBD significant_JJ emphasis_NN on_IN the_DT value_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN in_IN making_VBG the_DT decision_NN to_TO acquire_VB IBPP_NNP ._.
The_DT property_NN ,_, plant_NN and_CC equipment_NN of_IN IBPP_NNP complement_VBP the_DT Groups_NNS Injectables_NNPS business_NN ._.
74_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 36_CD ._.
Acquisition_NNP of_IN subsidiary_NN continued_VBD The_DT losses_NNS of_IN IBPP_NNP from_IN the_DT date_NN of_IN acquisition_NN that_WDT are_VBP included_VBN in_IN the_DT Groups_NNS income_NN statement_NN for_IN the_DT period_NN amounted_VBD to_TO $_$ 526,000_CD ._.
If_IN the_DT acquisition_NN of_IN IBPP_NNP had_VBD been_VBN completed_VBN on_IN the_DT first_JJ day_NN of_IN the_DT financial_JJ year_NN ,_, Group_NNP revenues_NNS for_IN the_DT year_NN would_MD have_VB been_VBN $_$ 262,914,000_CD and_CC the_DT Groups_NNS profit_NN attributable_JJ to_TO equity_NN holders_NNS of_IN the_DT parent_NN would_MD have_VB been_VBN $_$ 42,986,000_CD ._.
Net_JJ cash_NN from_IN operating_VBG activities_NNS 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Profit_NN before_IN tax_NN and_CC minority_NN interest_NN 64,409_CD 59,024_CD Adjustments_NNS for_IN :_: Depreciation_NN ,_, amortisation_NN and_CC impairment_NN of_IN Property_NN ,_, plant_NN and_CC equipment_NN 8,909_CD 6,680_CD Intangible_JJ assets_NNS 1,416_CD Financial_JJ assets_NNS 92_CD Results_NNS from_IN associated_VBN companies_NNS 1,449_CD 732_CD Losses_NNS on_IN disposal_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 440_CD 390_CD Movement_NNP on_IN provisions_NNS 404_CD 372_CD Deferred_JJ income_NN 174_CD 54_CD Cumulative_JJ effect_NN of_IN change_NN in_IN fair_JJ value_NN of_IN derivatives_NNS 164_CD 168_CD Stock_NNP options_NNS granted_VBD 713_CD 145_CD Deferred_JJ tax_NN 252_CD 41_CD Interest_NN and_CC bank_NN charges_NNS 5,211_CD 3,826_CD Cash_NN flow_NN before_IN working_VBG capital_NN 79,791_CD 69,952_CD Change_NNP in_IN trade_NN and_CC other_JJ receivables_NN 22,311_CD 10,426_CD Change_NNP in_IN due_JJ from_IN associate_JJ 691_CD 1,080_CD Change_NNP in_IN other_JJ current_JJ assets_NNS 369_CD 1,700_CD Income_NNP tax_NN recoverable_JJ 588_CD 707_CD Change_NNP in_IN inventories_NNS 13,306_CD 4,563_CD Change_NNP in_IN trade_NN and_CC other_JJ payables_NNS 16,064_CD 1,955_CD Change_NNP in_IN other_JJ current_JJ liabilities_NNS 4,029_CD 6,532_CD Cash_NN generated_VBN by_IN operations_NNS 55,737_CD 56,025_CD Income_NN tax_NN paid_VBN 17,800_CD 19,458_CD Interest_NN paid_VBN 5,224_CD 3,725_CD Net_JJ cash_NN generated_VBD from_IN operating_VBG activities_NNS 32,713_CD 32,842_CD 38_CD ._.
Contingent_JJ liabilities_NNS The_DT Group_NNP was_VBD contingently_RB liable_JJ for_IN letters_NNS of_IN guarantee_NN and_CC letters_NNS of_IN credit_NN totalling_VBG $_$ 11.1_CD million_CD and_CC $_$ 7.1_CD million_CD as_IN of_IN 31_CD December_NNP 2005_CD and_CC 2004_CD ,_, respectively_RB ._.
The_DT Group_NNP guaranteed_VBN 47.5_CD %_NN of_IN a_DT loan_NN granted_VBN to_TO its_PRP$ associate_JJ Al-Jazeera_NNP Pharmaceutical_NNP Industries_NNPS by_IN Saudi_NNP Industrial_NNP Development_NNP Fund_NNP SIDF_NNP for_IN a_DT total_JJ equivalent_JJ value_NN of_IN $_$ 11.2_CD million_CD and_CC $_$ 13.3_CD million_CD for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2005_CD and_CC 2004_CD ,_, respectively_RB ._.
The_DT integrated_JJ nature_NN of_IN the_DT Groups_NNS worldwide_JJ operations_NNS ,_, involving_VBG significant_JJ investment_NN in_IN research_NN and_CC strategic_JJ manufacture_NN at_IN a_DT limited_JJ number_NN of_IN locations_NNS ,_, with_IN consequential_JJ cross-border_JJ supply_NN routes_NNS into_IN numerous_JJ end-markets_NNS ,_, gives_VBZ rise_NN to_TO complexity_NN and_CC delay_NN in_IN negotiations_NNS with_IN revenue_NN authorities_NNS as_IN to_TO the_DT profits_NNS on_IN which_WDT individual_JJ Group_NNP companies_NNS are_VBP liable_JJ to_TO tax_NN ._.
Disagreements_NNS with_IN ,_, and_CC between_IN ,_, revenue_NN authorities_NNS as_IN to_TO intra-Group_JJ transactions_NNS ,_, in_IN particular_JJ the_DT price_NN at_IN which_WDT goods_NNS and_CC services_NNS should_MD be_VB transferred_VBN between_IN Group_NNP companies_NNS in_IN different_JJ tax_NN jurisdictions_NNS ,_, can_MD produce_VB conflicting_VBG claims_NNS from_IN revenue_NN authorities_NNS as_IN to_TO the_DT profits_NNS to_TO be_VB taxed_VBN in_IN individual_JJ territories_NNS ._.
Resolution_NN of_IN such_JJ issues_NNS is_VBZ ongoing_JJ ._.
In_IN common_JJ with_IN many_JJ other_JJ companies_NNS in_IN the_DT pharmaceutical_JJ industries_NNS the_DT Group_NNP is_VBZ subject_JJ to_TO certain_JJ legal_JJ and_CC product_NN liability_NN claims_NNS from_IN time_NN to_TO time_NN ._.
Whilst_NNP provisions_NNS have_VBP been_VBN made_VBN for_IN probable_JJ losses_NNS that_WDT management_NN deems_VBZ to_TO be_VB reasonable_JJ or_CC appropriate_JJ there_EX are_VBP inherent_JJ uncertainties_NNS connected_VBN with_IN these_DT estimates_NNS ._.
The_DT Group_NNP does_VBZ not_RB expect_VB the_DT resolution_NN of_IN uncertainties_NNS to_TO have_VB a_DT material_NN effect_NN on_IN the_DT consolidated_JJ financial_JJ statements_NNS ._.
Hikma_NNP Pharmaceuticals_NNP PLC_NNP equity_NN settled_VBD share_NN option_NN scheme_NN During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD ,_, the_DT Company_NN had_VBD one_CD share-based_JJ compensation_NN scheme_NN settled_VBN by_IN equity_NN instruments_NNS ._.
The_DT options_NNS over_IN these_DT instruments_NNS are_VBP settled_VBN in_IN equity_NN once_RB exercised_VBN ._.
Details_NNS of_IN the_DT grants_NNS under_IN the_DT scheme_NN are_VBP shown_VBN below_IN :_: 2005_CD Type_NN of_IN arrangement_NN General_NNP employee_NN share_NN option_NN plan_NN Date_NNP of_IN grant_NN 13_CD October_NNP 2005_CD Number_NNP granted_VBN 1,600,000_CD Contractual_JJ life_NN Ten_CD years_NNS Vesting_JJ conditions_NNS 20_CD %_NN per_IN year_NN for_IN five_CD years_NNS beginning_VBG on_IN the_DT first_JJ anniversary_NN of_IN the_DT grant_NN date_NN The_DT estimated_VBN fair_JJ value_NN of_IN each_DT share_NN option_NN granted_VBN in_IN the_DT general_JJ employee_NN share_NN option_NN plan_NN is_VBZ $_$ 0.74_CD ._.
This_DT was_VBD calculated_VBN by_IN applying_VBG a_DT binomial_JJ option_NN pricing_NN model_NN ._.
The_DT model_NN inputs_NNS were_VBD the_DT share_NN price_NN at_IN grant_NN date_NN of_IN $_$ 4.50_CD ,_, exercise_NN price_NN of_IN $_$ 4.50_CD ,_, expected_VBN volatility_NN of_IN 26.2_CD %_NN ,_, expected_VBN dividend_NN yield_NN of_IN 6.67_CD %_NN ,_, expected_VBN contractual_JJ life_NN of_IN 7.5_CD years_NNS ,_, and_CC a_DT risk-free_JJ interest_NN rate_NN of_IN 4.54_CD %_NN ._.
To_TO allow_VB for_IN the_DT effects_NNS of_IN early_JJ exercise_NN ,_, it_PRP was_VBD assumed_VBN that_IN the_DT employees_NNS would_MD exercise_VB the_DT options_NNS immediately_RB after_IN vesting_VBG date_NN ._.
2004_CD Type_NN of_IN arrangement_NN General_NNP employee_NN share_NN option_NN plan_NN Date_NNP of_IN grant_NN 12_CD October_NNP 2004_CD Number_NNP granted_VBN 9,520,000_CD Contractual_JJ life_NN Ten_CD years_NNS Vesting_JJ conditions_NNS 20_CD %_NN per_IN year_NN for_IN five_CD years_NNS beginning_VBG on_IN the_DT first_JJ anniversary_NN of_IN the_DT grant_NN date_NN The_DT estimated_VBN fair_JJ value_NN of_IN each_DT share_NN option_NN granted_VBN in_IN the_DT general_JJ employee_NN share_NN option_NN plan_NN is_VBZ $_$ 0.35_CD ._.
The_DT model_NN inputs_NNS were_VBD the_DT share_NN price_NN at_IN grant_NN date_NN of_IN $_$ 0.91_CD ,_, exercise_NN price_NN of_IN $_$ 0.91_CD ,_, expected_VBN volatility_NN of_IN 44.8_CD %_NN ,_, expected_VBN dividend_NN yield_NN of_IN 3.85_CD %_NN ,_, expected_VBN contractual_JJ life_NN of_IN 7.5_CD years_NNS ,_, and_CC a_DT risk-free_JJ interest_NN rate_NN of_IN 4.22_CD %_NN ._.
To_TO allow_VB for_IN the_DT effects_NNS of_IN early_JJ exercise_NN ,_, it_PRP was_VBD assumed_VBN that_IN the_DT employees_NNS would_MD exercise_VB the_DT options_NNS after_IN vesting_VBG date_NN ._.
Further_JJ details_NNS of_IN the_DT general_JJ employee_NN share_NN option_NN plan_NN are_VBP as_IN follows_VBZ :_: Weighted_JJ average_JJ Number_NN of_IN exercise_NN price_NN options_NNS $_$ Outstanding_JJ at_IN 1_CD January_NNP 2005_CD 9,520,000_CD 0.91_CD Granted_VBN during_IN the_DT year_NN 1,600,000_CD 4.50_CD Outstanding_JJ at_IN 31_CD December_NNP 2005_CD 11,120,000_CD 1.42_CD Exercisable_JJ at_IN 31_CD December_NNP 2005_CD 1,904,000_CD 0.91_CD A_DT stock_NN based_VBN compensation_NN charge_NN of_IN $_$ 712,000_CD 2004_CD :_: $_$ 145,000_CD has_VBZ been_VBN recorded_VBN in_IN the_DT income_NN statement_NN as_IN part_NN of_IN general_JJ and_CC administrative_JJ costs_NNS ._.
76_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 40_CD ._.
Operating_VBG lease_NN arrangements_NNS 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Minimum_NNP lease_NN payments_NNS under_IN operating_VBG leases_NNS recognized_VBN in_IN income_NN for_IN the_DT year_NN 655_CD 492_CD At_IN the_DT balance_NN sheet_NN date_NN ,_, the_DT Group_NNP had_VBD outstanding_JJ commitments_NNS for_IN future_JJ minimum_NN lease_NN payments_NNS under_IN non-cancellable_JJ operating_NN leases_NNS ,_, which_WDT fall_VBP due_JJ as_IN follows_VBZ :_: 2005_CD 2004_CD $_$ 000s_CD $_$ 000s_CD Within_IN one_CD year_NN 1,421_CD 857_CD In_IN the_DT second_JJ to_TO fifth_JJ years_NNS inclusive_JJ 4,320_CD 1,689_CD After_IN five_CD years_NNS 4,726_CD 10,467_CD 2,546_CD Operating_NN lease_NN payments_NNS represent_VBP rentals_NNS payable_JJ by_IN the_DT Group_NNP for_IN certain_JJ of_IN its_PRP$ office_NN properties_NNS ._.
Leases_NNS are_VBP negotiated_VBN for_IN an_DT average_JJ term_NN of_IN one_CD to_TO 7.5_CD years_NNS ._.
Related_VBN party_NN balances_NNS Transactions_NNS between_IN the_DT Company_NN and_CC its_PRP$ subsidiaries_NNS have_VBP been_VBN eliminated_VBN on_IN consolidation_NN and_CC are_VBP not_RB disclosed_VBN in_IN this_DT Note_NN ._.
Transactions_NNS between_IN the_DT Group_NNP and_CC its_PRP$ associate_NN and_CC other_JJ related_JJ parties_NNS are_VBP disclosed_VBN below_IN ._.
Trading_NN transactions_NNS :_: During_IN the_DT year_NN ,_, Group_NNP companies_NNS entered_VBD into_IN the_DT following_JJ transactions_NNS with_IN related_JJ parties_NNS :_: Al-Jazeera_NNP Pharmaceuticals_NNP Industries_NNPS :_: is_VBZ a_DT related_JJ party_NN of_IN the_DT Group_NNP because_IN it_PRP is_VBZ considered_VBN an_DT associate_JJ company_NN with_IN ownership_NN percentage_NN of_IN 47.5_CD %_NN ._.
Total_JJ purchases_NNS from_IN Al-Jazeera_NNP Pharmaceuticals_NNP Industries_NNPS during_IN 2005_CD amounted_VBD to_TO $_$ 3,619,000_CD and_CC total_JJ sales_NNS amounted_VBD to_TO $_$ 1,905,000_CD ._.
Balances_NNS due_RB from_IN Al-Jazeera_NNP Pharmaceuticals_NNP Industries_NNP at_IN the_DT end_NN of_IN 2005_CD amounted_VBD to_TO $_$ 2,304,000_CD ._.
Management_NN fees_NNS due_JJ to_TO the_DT Group_NNP amounted_VBD to_TO $_$ 1,016,000_CD as_IN at_IN 31_CD December_NNP 2004_CD :_: $_$ 333,000_CD ._.
Sales_NNS of_IN goods_NNS were_VBD made_VBN at_IN the_DT Groups_NNS usual_JJ list_NN prices_NNS and_CC purchases_NNS were_VBD made_VBN at_IN market_NN price_NN discounted_VBN to_TO reflect_VB the_DT quantity_NN of_IN goods_NNS purchased_VBN and_CC the_DT relationship_NN between_IN the_DT parties_NNS ._.
Darhold_NNP Limited_NNP :_: is_VBZ a_DT related_JJ party_NN of_IN the_DT Group_NNP because_IN it_PRP is_VBZ considered_VBN one_CD of_IN the_DT major_JJ shareholders_NNS of_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP with_IN ownership_NN percentage_NN of_IN 31.6_CD %_NN at_IN the_DT end_NN of_IN 2005_CD 2004_CD :_: nil_NN ._.
During_IN the_DT year_NN 2005_CD ,_, the_DT Group_NNP has_VBZ paid_VBN administrative_JJ expense_NN on_IN behalf_NN of_IN Darhold_NNP Limited_NNP for_IN a_DT total_JJ amount_NN of_IN $_$ 34,000_CD of_IN which_WDT the_DT balance_NN due_JJ to_TO the_DT Group_NNP by_IN year_NN end_NN amounted_VBD to_TO $_$ 21,000_CD 2004_CD :_: nil_NN ._.
Export_NNP &_CC Finance_NNP Bank_NNP Jordan_NNP :_: is_VBZ a_DT related_JJ party_NN of_IN the_DT Group_NNP because_IN two_CD board_NN members_NNS of_IN the_DT Bank_NNP are_VBP also_RB Board_NNP members_NNS at_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP total_JJ cash_NN balances_NNS at_IN Export_NNP &_CC Finance_NNP Bank_NNP Jordan_NNP were_VBD $_$ 5,180,000_CD 2004_CD :_: $_$ 40,774_CD ._.
Loans_NNS and_CC overdrafts_NNS granted_VBN by_IN Export_NNP &_CC Finance_NNP Bank_NNP to_TO the_DT Group_NNP amounted_VBD to_TO $_$ 1,201,000_CD 2004_CD :_: $_$ 1,028,000_CD with_IN interest_NN rates_NNS ranging_VBG between_IN 1_CD to_TO 1.25_CD %_NN LIBOR_NNP ._.
Total_JJ interest_NN expense_NN incurred_VBN against_IN Group_NNP facilities_NNS was_VBD $_$ 107,000_CD 2004_CD :_: $_$ 102,000_CD ._.
Jordan_NNP International_NNP Insurance_NNP Co_NNP :_: is_VBZ a_DT related_JJ party_NN of_IN the_DT Group_NNP because_IN one_CD board_NN member_NN of_IN the_DT company_NN is_VBZ also_RB a_DT Board_NNP member_NN at_IN Hikma_NNP Pharmaceuticals_NNP PLC._NNP ._.
Total_JJ insurance_NN premiums_NNS paid_VBN by_IN the_DT Group_NNP to_TO Jordan_NNP International_NNP Insurance_NNP Co_NNP in_IN the_DT year_NN 2005_CD were_VBD $_$ 1,185,000_CD 2004_CD :_: $_$ 834,000_CD ._.
The_DT Groups_NNS insurance_NN expense_NN for_IN Jordan_NNP International_NNP Insurance_NNP Co_NNP contracts_NNS in_IN the_DT year_NN 2005_CD was_VBD $_$ 967,000_CD 2004_CD :_: $_$ 928,000_CD ._.
The_DT amounts_NNS due_JJ to_TO Jordan_NNP International_NNP Insurance_NNP Co_NNP at_IN 2005_CD year_NN end_NN were_VBD $_$ 78,000_CD 2004_CD :_: $_$ 284,000_CD ._.
Mena_NNP Innovative_JJ Technology_NN :_: is_VBZ a_DT related_JJ party_NN of_IN the_DT Group_NNP because_IN the_DT majority_NN shareholder_NN is_VBZ Mr._NNP Nabil_NNP Rizks_NNP wife_NN the_DT head_NN of_IN the_DT Generics_NNPS business_NN ._.
Total_JJ purchases_NNS during_IN the_DT year_NN 2005_CD were_VBD $_$ 67,000_CD ._.
Purchases_NNS were_VBD made_VBN at_IN market_NN price_NN discounted_VBN to_TO reflect_VB the_DT quantity_NN of_IN goods_NNS purchased_VBN and_CC the_DT relationship_NN between_IN the_DT parties_NNS ._.
The_DT amounts_NNS due_JJ to_TO Mena_NNP Innovation_NNP Technology_NNP at_IN 2005_CD year_NN end_NN were_VBD $_$ 10,000_CD 2004_CD :_: $_$ 6,000_CD ._.
Tunisian_JJ Companies_NNS :_: Amounts_NNS due_RB from_IN Tunisian_JJ companies_NNS include_VBP $_$ 162,000_CD 2004_CD :_: $_$ 162,000_CD ,_, 188,000_CD 2004_CD :_: $_$ 514,000_CD and_CC $_$ 459,000_CD 2004_CD :_: $_$ 554,000_CD due_JJ form_NN Societe_NNP Hikma_NNP Pharma_NNP Tunisia_NNP ,_, Societe_NNP Hikma_NNP Ibn_NNP Al_NNP Baytar_NNP Limited_NNP Tunisia_NNP and_CC Societe_NNP DIndustries_NNP Pharmaceutiques_NNP Ibn_NNP Al_NNP Baytar_NNP S._NNP A._NNP Tunisia_NNP ,_, respectively_RB ._.
West-ward_JJ Pharmaceuticals_NNS USA_NNP :_: Certain_NNP expenses_NNS of_IN the_DT Chairman_NNP were_VBD paid_VBN in_IN the_DT USA_NNP by_IN West-ward_JJ Pharmaceuticals_NNS and_CC reimbursed_VBN by_IN the_DT Chairman_NNP ._.
At_IN 31_CD December_NNP 2005_CD ,_, the_DT balance_NN outstanding_JJ amounted_VBD to_TO $_$ 120,000_CD 2004_CD :_: nil_NN which_WDT has_VBZ been_VBN repaid_VBN since_IN the_DT year_NN end_NN ._.
Related_VBN party_NN balances_NNS continued_VBD Remuneration_NNP of_IN key_JJ management_NN personnel_NNS The_DT remuneration_NN of_IN the_DT two_CD Executive_NNP Directors_NNS and_CC the_DT key_JJ management_NN personnel_NNS of_IN the_DT Group_NNP are_VBP set_VBN out_RP below_IN in_IN aggregate_NN for_IN each_DT of_IN the_DT categories_NNS specified_VBN in_IN IAS_NNP 24_CD Related_NNP Party_NNP Disclosures_NNS ._.
Further_JJ information_NN about_IN the_DT remuneration_NN of_IN the_DT individual_JJ Directors_NNS is_VBZ provided_VBN in_IN the_DT audited_JJ part_NN of_IN the_DT Board_NNP report_NN on_IN remuneration_NN on_IN pages_NNS 40_CD to_TO 42_CD ._.
Hikma_NNP Pharmaceuticals_NNP PLC_NNP main_JJ subsidiaries_NNS The_DT main_JJ subsidiaries_NNS of_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP are_VBP as_IN follows_VBZ :_: Ownership_NN %_NN Ownership_NN %_NN Ordinary_NNP Ordinary_NNP Shares_NNP Shares_NNP Companys_NNP name_NN Established_VBN in_IN 2005_CD 2004_CD Hikma_NNP Pharmaceuticals_NNP Co._NNP ._.
Jordan_NNP 100_CD 100_CD Trust_NNP Pharma_NNP Co._NNP ._.
Algeria_NNP 100_CD 100_CD Hikma_NNP Farmacutica_NNP Portugal_NNP 100_CD 100_CD West-ward_JJ Pharmaceutical_NNP Corp._NNP ._.
USA_NNP 100_CD 100_CD Pharma_NNP Ixir_NNP Co._NNP ._.
Sudan_NNP 51_CD 51_CD Istituto_NNP Biochimico_NNP Pavese_NNP Pharma_NNP S._NNP P._NNP A_NNP IBPP_NNP Italy_NNP 100_CD Acquired_VBN during_IN the_DT year_NN ._.
Hikma_NNP Pharmaceuticals_NNP PLC_NNP defined_VBD contribution_NN retirement_NN benefit_NN plan_NN Hikma_NNP Pharmaceuticals_NNP PLC_NNP has_VBZ defined_VBN contribution_NN retirement_NN plans_NNS in_IN two_CD of_IN its_PRP$ subsidiaries_NNS :_: West-ward_JJ Pharmaceuticals_NNS USA_NNP and_CC Hikma_NNP Pharmaceuticals_NNP Jordan_NNP ._.
The_DT details_NNS of_IN each_DT contribution_NN plan_NN are_VBP as_IN follows_VBZ :_: Hikma_NNP Pharmaceuticals_NNP Jordan_NNP :_: The_NNP Group_NNP currently_RB has_VBZ an_DT employee_NN saving_VBG plan_NN wherein_IN the_DT Group_NNP fully_RB matches_VBZ employees_NNS contributions_NNS ,_, which_WDT are_VBP fixed_VBN at_IN 5_CD %_NN of_IN salary_NN ._.
Employees_NNS are_VBP entitled_VBN to_TO 30_CD %_NN of_IN the_DT Group_NNP contributions_NNS after_IN three_CD years_NNS of_IN employment_NN with_IN the_DT Group_NNP and_CC 10_CD %_NN for_IN each_DT subsequent_JJ year_NN ._.
Employees_NNS fully_RB vest_NN in_IN the_DT Group_NNP contributions_NNS after_IN ten_CD years_NNS of_IN employment_NN ._.
The_DT Groups_NNS contributions_NNS were_VBD $_$ 410,000_CD and_CC $_$ 321,000_CD for_IN the_DT years_NNS ended_VBN 2005_CD and_CC 2004_CD respectively_RB ._.
West-ward_JJ USA_NNP :_: 401_CD k_NN salary_NN saving_VBG plan_NN ._.
Prior_RB to_TO 2001_CD ,_, West-ward_JJ USA_NNP established_VBD a_DT 401_CD k_NN defined_VBN contribution_NN plan_NN ,_, which_WDT allows_VBZ all_DT eligible_JJ employees_NNS to_TO defer_VB a_DT portion_NN of_IN their_PRP$ income_NN through_IN contributions_NNS to_TO the_DT plan_NN ._.
All_DT employees_NNS not_RB covered_VBN by_IN any_DT collective_JJ bargaining_NN agreement_NN are_VBP eligible_JJ after_IN being_VBG employed_VBN for_IN one_CD year_NN ._.
Employees_NNS can_MD defer_VB up_RP to_TO 25_CD %_NN of_IN their_PRP$ gross_JJ salary_NN into_IN the_DT plan_NN ,_, not_RB to_TO exceed_VB $_$ 14,000_CD and_CC $_$ 13,000_CD for_IN 2005_CD and_CC 2004_CD ,_, respectively_RB ,_, not_RB including_VBG catch-up_NN contributions_NNS available_JJ to_TO eligible_JJ employees_NNS as_IN outlined_VBN by_IN the_DT Internal_NNP Revenue_NNP Service_NNP ._.
The_DT company_NN matches_VBZ 40_CD %_NN of_IN the_DT employees_NNS eligible_JJ contribution_NN ._.
Employer_NN contributions_NNS vest_NN 0_CD %_NN after_IN one_CD year_NN of_IN service_NN ,_, 50_CD %_NN after_IN two_CD years_NNS of_IN service_NN and_CC 100_CD %_NN after_IN three_CD years_NNS of_IN service_NN ._.
Employees_NNS are_VBP considered_VBN to_TO have_VB completed_VBN one_CD year_NN of_IN service_NN for_IN purposes_NNS of_IN vesting_VBG upon_IN the_DT completion_NN of_IN 1,000_CD hours_NNS of_IN service_NN at_IN any_DT time_NN during_IN a_DT plan_NN year_NN ._.
Employer_NN contributions_NNS to_TO the_DT plan_NN as_IN at_IN 31_CD December_NNP 2005_CD and_CC 2004_CD amounted_VBD to_TO $_$ 275,000_CD and_CC $_$ 294,000_CD respectively_RB ._.
The_DT assets_NNS of_IN the_DT plans_NNS are_VBP held_VBN separately_RB from_IN those_DT of_IN the_DT Group_NNP ._.
The_DT only_JJ obligation_NN of_IN the_DT Group_NNP with_IN respect_NN to_TO the_DT retirement_NN benefit_NN plans_NNS is_VBZ to_TO make_VB specified_VBN contributions_NNS ._.
78_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 44_CD ._.
Hikma_NNP Pharmaceuticals_NNP PLC_NNP Consolidated_NNP income_NN statement_NN from_IN date_NN of_IN incorporation_NN on_IN 8_CD September_NNP 2005_CD to_TO 31_CD December_NNP 2005_CD 2005_CD $_$ 000s_CD Net_JJ sales_NNS 90,822_CD Cost_NN of_IN sales_NNS 45,600_CD Gross_NNP profit_NN 45,222_CD Sales_NNS and_CC marketing_NN 9,842_CD General_NNP and_CC administrative_JJ 9,182_CD Research_NN and_CC development_NN 6,858_CD Other_JJ operating_NN expenses_NNS ,_, net_JJ 2,867_CD Share_NN of_IN results_NNS of_IN associate_JJ 1,383_CD Operating_NN profit_NN 23,590_CD Flotation_NN costs_NNS 1,426_CD Finance_NNP income_NN 831_CD Finance_NNP cost_NN 1,789_CD Other_JJ expense_NN 1,088_CD Profit_NN before_IN tax_NN 20,118_CD Tax_NNP 4,376_CD Profit_NN for_IN the_DT period_NN 15,742_CD Attributable_JJ to_TO :_: Equity_NNP holders_NNS of_IN the_DT parent_NN 15,466_CD Minority_NNP interest_NN 276_CD 15,742_CD The_DT profit_NN and_CC loss_NN account_NN above_IN is_VBZ required_VBN by_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC covers_VBZ the_DT first_JJ statutory_JJ accounting_NN reference_NN period_NN of_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP from_IN its_PRP$ date_NN of_IN incorporation_NN on_IN 8_CD September_NNP 2005_CD to_TO 31_CD December_NNP 2005_CD ._.
Disclosure_NN notes_NNS for_IN this_DT period_NN are_VBP not_RB presented_VBN as_IN the_DT Directors_NNS do_VBP not_RB believe_VB they_PRP would_MD provide_VB meaningful_JJ information_NN to_TO users_NNS of_IN the_DT accounts_NNS ._.
Directors_NNS remuneration_NN for_IN this_DT period_NN is_VBZ included_VBN within_IN the_DT amounts_NNS disclosed_VBN in_IN the_DT Board_NNP report_NN on_IN remuneration_NN on_IN pages_NNS 37_CD to_TO 42_CD which_WDT include_VBP remuneration_NN for_IN the_DT period_NN from_IN 8_CD September_NNP or_CC ,_, if_IN later_RB ,_, date_NN of_IN appointment_NN until_IN the_DT year_NN end_NN ._.
Hikma_NNP Pharmaceuticals_NNP PLC_NNP continued_VBD Consolidated_NNP cash_NN flow_NN statement_NN from_IN date_NN of_IN incorporation_NN on_IN 8_CD September_NNP 2005_CD to_TO 31_CD December_NNP 2005_CD $_$ 000s_CD Net_JJ cash_NN from_IN operating_VBG activities_NNS 20,847_CD Cash_NN flows_VBZ from_IN investing_VBG activities_NNS Purchases_NNS of_IN property_NN ,_, plant_NN and_CC equipment_NN 14,747_CD Proceeds_NNS from_IN disposal_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 873_CD Purchase_NN of_IN intangible_JJ assets_NNS 89_CD Investment_NN in_IN financial_JJ and_CC other_JJ assets_NNS 593_CD Investment_NN in_IN available_JJ for_IN sale_NN securities_NNS 16_CD Acquisition_NNP of_IN subsidiary_NN 40_CD Net_JJ cash_NN used_VBN in_IN investing_VBG activities_NNS 14,434_CD Cash_NN flows_VBZ from_IN financing_VBG activities_NNS Increase_VBP in_IN collateralised_JJ cash_NN 5,120_CD Increase_VBP in_IN long-term_JJ financial_JJ debts_NNS 5,471_CD Repayment_NN of_IN long-term_JJ financial_JJ debts_NNS 20,500_CD Repayment_NN of_IN short-term_JJ financial_JJ debts_NNS 15,041_CD Payment_NN of_IN capital_NN lease_NN obligations_NNS 2,310_CD Dividends_NNPS paid_VBD 10,835_CD Proceeds_NNS on_IN issue_NN of_IN new_JJ shares_NNS 124,913_CD Payments_NNS on_IN issue_NN of_IN new_JJ shares_NNS 10,810_CD Net_JJ cash_NN generated_VBD from_IN financing_VBG activities_NNS 65,768_CD Net_JJ increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 72,181_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN the_DT beginning_NN of_IN the_DT period_NN 61,164_CD Net_JJ effect_NN of_IN foreign_JJ exchange_NN rate_NN changes_NNS 2,297_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN period_NN end_NN 135,642_CD 80_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS continued_VBD 44_CD ._.
Hikma_NNP Pharmaceuticals_NNP PLC_NNP continued_VBD Consolidated_NNP cash_NN flow_NN statement_NN from_IN date_NN of_IN incorporation_NN on_IN 8_CD September_NNP 2005_CD to_TO 31_CD December_NNP 2005_CD $_$ 000s_CD Profit_NN before_IN tax_NN 20,118_CD Adjustments_NNS for_IN :_: Depreciation_NN ,_, amortisation_NN and_CC impairment_NN of_IN :_: Property_NN ,_, plant_NN and_CC equipment_NN 3,950_CD Intangible_JJ assets_NNS 522_CD Results_NNS from_IN associated_VBN companies_NNS 1,383_CD Losses_NNS on_IN disposal_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 556_CD Movements_NNS on_IN provision_NN 375_CD Deferred_JJ revenue_NN 46_CD Cumulative_JJ effect_NN of_IN change_NN in_IN fair_JJ value_NN of_IN derivatives_NNS 236_CD Stock_NNP options_NNS granted_VBD 273_CD Deferred_JJ tax_NN 744_CD Interest_NN and_CC bank_NN charges_NNS 2,089_CD Cash_NN flow_NN before_IN working_VBG capital_NN 25,946_CD Change_NNP in_IN accounts_NNS receivables_NNS 6,155_CD Change_NNP in_IN other_JJ current_JJ assets_NNS 3,484_CD Change_NNP in_IN inventories_NNS 992_CD Change_NNP in_IN trade_NN accounts_NNS payable_JJ 7,318_CD Change_NNP in_IN other_JJ current_JJ liabilities_NNS 8,186_CD Cash_NN generated_VBN by_IN operations_NNS 28,493_CD Income_NN tax_NN paid_VBN 5,545_CD Interest_NN paid_VBN 2,101_CD Net_JJ cash_NN generated_VBD from_IN operating_VBG activities_NNS 20,847_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP 81_CD Directors_NNS responsibilities_NNS Company_NN Law_NN requires_VBZ the_DT Directors_NNS to_TO prepare_VB accounts_NNS and_CC Notes_NNS for_IN each_DT financial_JJ year_NN ,_, which_WDT give_VBP a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT state_NN of_IN affairs_NNS of_IN the_DT Company_NN as_IN at_IN the_DT end_NN of_IN the_DT financial_JJ year_NN and_CC the_DT income_NN statement_NN of_IN the_DT Company_NN for_IN that_DT period_NN ._.
In_IN preparing_VBG those_DT accounts_NNS and_CC Notes_NNS the_DT Directors_NNS are_VBP required_VBN to_TO :_: select_JJ suitable_JJ accounting_NN policies_NNS and_CC apply_VB them_PRP consistently_RB :_: make_VB judgements_NNS and_CC estimates_NNS that_WDT are_VBP reasonable_JJ and_CC prudent_JJ :_: and_CC state_NN whether_IN applicable_JJ accounting_NN standards_NNS have_VBP been_VBN followed_VBN ._.
The_DT Directors_NNS are_VBP responsible_JJ for_IN ensuring_VBG proper_JJ accounting_NN records_NNS are_VBP kept_VBN which_WDT disclose_VBP with_IN reasonable_JJ accuracy_NN at_IN any_DT time_NN the_DT financial_JJ position_NN of_IN the_DT Company_NN and_CC enable_VB them_PRP to_TO ensure_VB that_IN the_DT accounts_NNS and_CC Notes_NNS comply_VBP with_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
They_PRP are_VBP also_RB responsible_JJ for_IN the_DT Companys_NNP system_NN of_IN internal_JJ control_NN ,_, for_IN safeguarding_VBG of_IN the_DT assets_NNS of_IN the_DT Company_NN and_CC hence_RB for_IN taking_VBG reasonable_JJ steps_NNS for_IN the_DT prevention_NN and_CC detection_NN of_IN fraud_NN and_CC other_JJ irregularities_NNS After_IN making_VBG enquiries_NNS ,_, the_DT Directors_NNS have_VBP a_DT reasonable_JJ expectation_NN that_IN the_DT Company_NN has_VBZ adequate_JJ resources_NNS to_TO continue_VB in_IN operational_JJ existence_NN for_IN the_DT foreseeable_JJ future_NN ._.
For_IN this_DT reason_NN ,_, they_PRP continue_VBP to_TO adopt_VB the_DT going_VBG concern_NN basis_NN in_IN preparing_VBG the_DT financial_JJ statements_NNS ._.
82_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Independent_NNP auditors_NNS report_VBP to_TO the_DT members_NNS of_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP We_PRP have_VBP audited_VBN the_DT individual_JJ company_NN financial_JJ statements_NNS of_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD which_WDT comprise_VBP the_DT balance_NN sheet_NN ,_, the_DT cash_NN flow_NN statement_NN and_CC the_DT related_JJ Notes_NNP 1_CD to_TO 9_CD ._.
These_DT individual_JJ company_NN financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN the_DT accounting_NN policies_NNS set_VBN out_RP therein_RB ._.
The_DT corporate_JJ governance_NN statement_NN and_CC the_DT Directors_NNS remuneration_NN report_NN are_VBP included_VBN in_IN the_DT Group_NNP annual_JJ report_NN of_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD ._.
We_PRP have_VBP reported_VBN separately_RB on_IN the_DT Group_NNP financial_JJ statements_NNS of_IN Hikma_NNP Pharmaceuticals_NNP PLC_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD and_CC on_IN the_DT information_NN in_IN the_DT Directors_NNS remuneration_NN report_NN that_WDT is_VBZ described_VBN as_IN having_VBG been_VBN audited_VBN ._.
This_DT report_NN is_VBZ made_VBN solely_RB to_TO the_DT Companys_NNPS members_NNS ,_, as_IN a_DT body_NN ,_, in_IN accordance_NN with_IN section_NN 235_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Our_PRP$ audit_NN work_NN has_VBZ been_VBN undertaken_VBN so_RB that_IN we_PRP might_MD state_VB to_TO the_DT Companys_NNPS members_NNS those_DT matters_NNS we_PRP are_VBP required_VBN to_TO state_NN to_TO them_PRP in_IN an_DT auditors_NNS report_NN and_CC for_IN no_DT other_JJ purpose_NN ._.
To_TO the_DT fullest_JJS extent_NN permitted_VBN by_IN law_NN ,_, we_PRP do_VBP not_RB accept_VB or_CC assume_VB responsibility_NN to_TO anyone_NN other_JJ than_IN the_DT Company_NN and_CC the_DT Companys_NNPS members_NNS as_IN a_DT body_NN ,_, for_IN our_PRP$ audit_NN work_NN ,_, for_IN this_DT report_NN ,_, or_CC for_IN the_DT opinions_NNS we_PRP have_VBP formed_VBN ._.
Respective_JJ responsibilities_NNS of_IN Directors_NNS and_CC auditors_NNS The_DT Directors_NNS responsibilities_NNS for_IN preparing_VBG the_DT annual_JJ report_NN and_CC the_DT financial_JJ statements_NNS in_IN accordance_NN with_IN applicable_JJ law_NN and_CC International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP as_IN adopted_VBN for_IN use_NN in_IN the_DT European_NNP Union_NNP are_VBP set_VBN out_RP in_IN the_DT statement_NN of_IN Directors_NNS responsibilities_NNS ._.
Our_PRP$ responsibility_NN is_VBZ to_TO audit_VB the_DT individual_JJ company_NN financial_JJ statements_NNS in_IN accordance_NN with_IN relevant_JJ United_NNP Kingdom_NNP legal_JJ and_CC regulatory_JJ requirements_NNS and_CC International_NNP Standards_NNPS on_IN Auditing_NNP UK_NNP and_CC Ireland_NNP ._.
We_PRP report_VBP to_TO you_PRP our_PRP$ opinion_NN as_IN to_TO whether_IN the_DT individual_JJ company_NN financial_JJ statements_NNS give_VBP a_DT true_JJ and_CC fair_JJ view_NN in_IN accordance_NN with_IN the_DT relevant_JJ financial_JJ reporting_NN framework_NN and_CC whether_IN the_DT financial_JJ statements_NNS have_VBP been_VBN properly_RB prepared_VBN in_IN accordance_NN with_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC Article_NNP 4_CD of_IN the_DT IAS_NNP Regulation_NN ._.
We_PRP report_VBP to_TO you_PRP if_IN ,_, in_IN our_PRP$ opinion_NN ,_, the_DT Directors_NNS report_NN is_VBZ not_RB consistent_JJ with_IN the_DT individual_JJ company_NN financial_JJ statements_NNS ._.
We_PRP also_RB report_VBP to_TO you_PRP if_IN the_DT Company_NN has_VBZ not_RB kept_VBN proper_JJ accounting_NN records_NNS ,_, if_IN we_PRP have_VBP not_RB received_VBN all_PDT the_DT information_NN and_CC explanations_NNS we_PRP require_VBP for_IN our_PRP$ audit_NN ,_, or_CC if_IN information_NN specified_VBN by_IN law_NN regarding_VBG Directors_NNS remuneration_NN and_CC other_JJ transactions_NNS is_VBZ not_RB disclosed_VBN ._.
We_PRP read_VBP the_DT Directors_NNS report_NN and_CC the_DT other_JJ information_NN contained_VBN in_IN the_DT annual_JJ report_NN for_IN the_DT above_JJ year_NN as_IN described_VBN in_IN the_DT contents_NNS section_NN ._.
We_PRP consider_VBP the_DT implications_NNS for_IN our_PRP$ report_NN if_IN we_PRP become_VBP aware_JJ of_IN any_DT apparent_JJ misstatements_NNS or_CC material_NN inconsistencies_NNS with_IN the_DT individual_JJ company_NN financial_JJ statements_NNS ._.
Basis_NN of_IN audit_NN opinion_NN We_PRP conducted_VBD our_PRP$ audit_NN in_IN accordance_NN with_IN International_NNP Standards_NNPS on_IN Auditing_NNP UK_NNP and_CC Ireland_NNP issued_VBN by_IN the_DT Auditing_NNP Practices_NNPS Board_NNP ._.
An_DT audit_NN includes_VBZ examination_NN ,_, on_IN a_DT test_NN basis_NN ,_, of_IN evidence_NN relevant_JJ to_TO the_DT amounts_NNS and_CC disclosures_NNS in_IN the_DT individual_JJ company_NN financial_JJ statements_NNS ._.
It_PRP also_RB includes_VBZ an_DT assessment_NN of_IN the_DT significant_JJ estimates_NNS and_CC judgements_NNS made_VBN by_IN the_DT Directors_NNS in_IN the_DT preparation_NN of_IN the_DT financial_JJ statements_NNS ,_, and_CC of_IN whether_IN the_DT accounting_NN policies_NNS are_VBP appropriate_JJ to_TO the_DT Companys_NNPS circumstances_NNS ,_, consistently_RB applied_VBN and_CC adequately_RB disclosed_VBN ._.
We_PRP planned_VBD and_CC performed_VBD our_PRP$ audit_NN so_RB as_IN to_TO obtain_VB all_PDT the_DT information_NN and_CC explanations_NNS which_WDT we_PRP considered_VBD necessary_JJ in_IN order_NN to_TO provide_VB us_PRP with_IN sufficient_JJ evidence_NN to_TO give_VB reasonable_JJ assurance_NN that_IN the_DT individual_JJ company_NN financial_JJ statements_NNS are_VBP free_JJ from_IN material_NN misstatement_NN ,_, whether_IN caused_VBN by_IN fraud_NN or_CC other_JJ irregularity_NN or_CC error_NN ._.
In_IN forming_VBG our_PRP$ opinion_NN we_PRP also_RB evaluated_VBD the_DT overall_JJ adequacy_NN of_IN the_DT presentation_NN of_IN information_NN in_IN the_DT individual_JJ company_NN financial_JJ statements_NNS ._.
Opinion_NN In_IN our_PRP$ opinion_NN :_: the_DT individual_JJ company_NN financial_JJ statements_NNS give_VBP a_DT true_JJ and_CC fair_JJ view_NN ,_, in_IN accordance_NN with_IN IFRS_NNP as_IN adopted_VBN for_IN use_NN in_IN the_DT European_NNP Union_NNP as_IN applied_VBN in_IN accordance_NN with_IN the_DT requirements_NNS of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, of_IN the_DT state_NN of_IN the_DT Companys_NNP affairs_NNS as_IN at_IN 31_CD December_NNP 2005_CD :_: and_CC the_DT individual_JJ company_NN financial_JJ statements_NNS have_VBP been_VBN properly_RB prepared_VBN in_IN accordance_NN with_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC Article_NNP 4_CD of_IN the_DT IAS_NNP Regulation_NN ._.
Deloitte_NNP &_CC Touche_NNP LLP_NNP Chartered_NNP Accountants_NNPS and_CC Registered_NNP Auditors_NNS London_NNP ,_, United_NNP Kingdom_NNP 28_CD March_NNP 2006_CD ._.
Hikma_NNP Pharmaceuticals_NNP PLC_NNP 83_CD Company_NN balance_NN sheet_NN as_IN of_IN 31_CD December_NNP 2005_CD 2005_CD Notes_NNS $_$ 000s_CD Non-current_JJ assets_NNS Investment_NN in_IN subsidiary_NN 2_CD 740,298_CD Due_JJ from_IN subsidiaries_NNS 54,000_CD 794,298_CD Current_JJ assets_NNS Other_JJ current_JJ assets_NNS 422_CD Cash_NN and_CC cash_NN equivalents_NNS 3_CD 58,732_CD Dividends_NNPS receivable_NN 1,500_CD 60,654_CD Total_JJ assets_NNS 854,952_CD Current_JJ liabilities_NNS Other_JJ payables_NNS 4_CD 994_CD Other_JJ current_JJ liabilities_NNS 354_CD Income_NNP tax_NN provision_NN 110_CD 1,458_CD Non-current_JJ liabilities_NNS Due_JJ to_TO subsidiaries_NNS 4,836_CD Total_JJ liabilities_NNS 6,294_CD Net_JJ assets_NNS 848,658_CD Equity_NN Share_NN capital_NN 7_CD 29,457_CD Share_NN premium_NN account_NN 8_CD 817,443_CD Retained_VBN earnings_NNS 9_CD 1,758_CD Equity_NN attributable_JJ to_TO equity_NN holders_NNS to_TO the_DT parent_NN 848,658_CD The_DT financial_JJ statements_NNS were_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: Samih_NNP Darwazah_NNP Director_NNP 28_CD March_NNP 2006_CD 84_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Company_NNP statement_NN of_IN changes_NNS in_IN equity_NN for_IN the_DT period_NN ended_VBD 31_CD December_NNP 2005_CD Paid_VBD up_RP Share_NN Retained_VBN capital_NN premium_NN earnings_NNS Total_JJ Notes_NNP $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD $_$ 000s_CD At_IN 8_CD September_NNP 2005_CD 8_CD Issue_NN of_IN share_NN capital_NN 29,457_CD 817,443_CD 846,900_CD Net_JJ income_NN for_IN the_DT period_NN 9_CD 1,758_CD 1,758_CD At_IN 31_CD December_NNP 2005_CD 29,457_CD 817,443_CD 1,758_CD 848,658_CD As_IN permitted_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT income_NN statement_NN of_IN the_DT Company_NN is_VBZ not_RB presented_VBN as_IN part_NN of_IN these_DT accounts_NNS ._.
Hikma_NNP Pharmaceuticals_NNP PLC_NNP 85_CD Cash_NN flow_NN statement_NN for_IN the_DT period_NN ended_VBD 31_CD December_NNP 2005_CD 2005_CD $_$ 000s_CD Profit_NN before_IN tax_NN 1,695_CD Stock_NNP options_NNS granted_VBD 172_CD Change_NNP in_IN other_JJ current_JJ assets_NNS 422_CD Change_NNP in_IN other_JJ payables_NNS 994_CD Change_NNP in_IN other_JJ current_JJ liabilities_NNS 354_CD Net_JJ cash_NN used_VBN in_IN operating_VBG activities_NNS 2,793_CD Investing_VBG activities_NNS Change_NNP in_IN amounts_NNS due_JJ from_IN subsidiaries_NNS 49,164_CD Change_NNP in_IN dividends_NNS receivable_JJ 1,500_CD Investment_NN in_IN subsidiary_NN 7,500_CD Net_JJ cash_NN used_VBN in_IN investing_VBG activities_NNS 58,164_CD Financing_NN activities_NNS Proceeds_NNS from_IN share_NN issuance_NN 124,913_CD Costs_NNS of_IN share_NN issue_NN 10,810_CD Net_JJ cash_NN from_IN financing_VBG activities_NNS 114,103_CD Net_JJ increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 58,732_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN beginning_NN of_IN period_NN Cash_NN and_CC cash_NN equivalents_NNS at_IN end_NN of_IN period_NN 58,732_CD 86_CD Hikma_NNP Pharmaceuticals_NNP PLC_NNP Notes_NNP to_TO the_DT separate_JJ financial_JJ statements_NNS 1_CD ._.
Significant_JJ accounting_NN policies_NNS The_DT separate_JJ financial_JJ statements_NNS of_IN the_DT Company_NN are_VBP presented_VBN as_IN required_VBN by_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
As_IN permitted_VBN by_IN that_DT Act_NNP ,_, the_DT separate_JJ financial_JJ statements_NNS have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS and_CC UK_NNP law_NN ._.
The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN on_IN the_DT historical_JJ cost_NN basis_NN ._.
The_DT principal_JJ accounting_NN policies_NNS adopted_VBN are_VBP the_DT same_JJ as_IN those_DT set_VBN out_RP in_IN Note_NN 2_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS with_IN the_DT addition_NN of_IN the_DT policy_NN as_IN noted_VBN below_IN ._.
Investments_NNP in_IN subsidiaries_NNS are_VBP stated_VBN at_IN cost_NN less_RBR ,_, where_WRB appropriate_JJ ,_, provisions_NNS for_IN impairment_NN ._.
Investment_NN in_IN subsidiary_NN Investment_NN in_IN subsidiary_NN represents_VBZ 100_CD %_NN share_NN in_IN Hikma_NNP Pharma_NNP Limited_NNP Jersey_NNP ,_, the_DT cost_NN method_NN is_VBZ being_VBG used_VBN to_TO account_VB for_IN this_DT investment_NN ._.
Financial_JJ assets_NNS Cash_NN and_CC cash_NN equivalents_NNS These_DT comprise_VBP cash_NN held_VBN by_IN the_DT company_NN and_CC short-term_JJ bank_NN deposits_NNS with_IN an_DT original_JJ maturity_NN of_IN three_CD months_NNS or_CC less_JJR ._.
The_DT carrying_VBG amount_NN of_IN these_DT assets_NNS approximates_VBZ their_PRP$ fair_JJ value_NN ._.
Financial_NNP liabilities_NNS Other_JJ payables_NNS The_DT Directors_NNS consider_VBP that_IN the_DT carrying_VBG amount_NN of_IN other_JJ payables_NNS approximates_VBZ to_TO their_PRP$ fair_JJ value_NN ._.
Staff_NN costs_NNS Hikma_NNP Pharmaceuticals_NNP PLC_NNP currently_RB has_VBZ two_CD employees_NNS :_: total_JJ compensation_NN paid_VBN to_TO them_PRP amounted_VBD to_TO $_$ 117,000_CD of_IN which_WDT salaries_NNS and_CC wages_NNS compromise_VB an_DT amount_NN of_IN $_$ 73,000_CD the_DT remaining_VBG balance_NN of_IN $_$ 44,000_CD represent_VBP social_JJ security_NN and_CC other_JJ benefits_NNS ._.
Stock_NNP options_NNS The_DT details_NNS of_IN the_DT stock_NN compensation_NN scheme_NN were_VBD provided_VBN in_IN Note_NN 39_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
The_DT number_NN of_IN options_NNS granted_VBN to_TO the_DT employees_NNS of_IN the_DT Company_NN including_VBG Directors_NNS was_VBD 2,560,000_CD and_CC the_DT total_JJ amount_NN of_IN the_DT compensation_NN expenses_NNS charged_VBD to_TO income_NN statement_NN is_VBZ $_$ 172,000_CD ._.
Share_NN capital_NN 2005_CD $_$ 000s_CD Authorised_VBN :_: 500,000,000_CD Ordinary_NNP Shares_NNP of_IN 10_CD pence_NN each_DT 88,700_CD 49,998_CD non-voting_JJ ,_, redeemable_JJ preference_NN shares_NNS of_IN 1_CD each_DT 90_CD Issued_VBN and_CC fully_RB paid_VBN included_VBN in_IN shareholders_NNS equity_NN 166,798,407_CD Ordinary_NNP Shares_NNP of_IN 10_CD pence_NN each_DT 29,457_CD Issued_VBN and_CC fully_RB paid_VBN included_VBN in_IN liabilities_NNS 49,998_CD non-voting_JJ ,_, redeemable_JJ preference_NN shares_NNS of_IN 1_CD each_DT 90_CD The_DT details_NNS of_IN the_DT issue_NN of_IN the_DT share_NN capital_NN in_IN the_DT period_NN are_VBP given_VBN in_IN Note_NN 31_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
Share_NN premium_NN Share_NN premium_NN $_$ 000s_CD Balance_NN at_IN 8_CD September_NNP 2005_CD Premium_NNP arising_VBG on_IN issue_NN of_IN equity_NN shares_NNS 828,253_CD Expenses_NNS of_IN issue_NN of_IN equity_NN shares_NNS 10,810_CD Balance_NN at_IN 31_CD December_NNP 2005_CD 817,443_CD 9_CD ._.
Retained_VBN earnings_NNS Included_VBD in_IN the_DT retained_VBN earnings_NNS an_DT amount_NN of_IN $_$ 172,000_CD represents_VBZ the_DT current_JJ year_NN charge_NN of_IN stock_NN option_NN expenses_NNS ._.
